The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
A fibrin-stabilizing plasma enzyme (TRANSGLUTAMINASES) that is activated by THROMBIN and CALCIUM to form FACTOR XIIIA. It is important for stabilizing the formation of the fibrin polymer (clot) which culminates the coagulation cascade.
Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
Activated form of factor XI. In the intrinsic pathway, Factor XI is activated to XIa by factor XIIa in the presence of cofactor HMWK; (HIGH MOLECULAR WEIGHT KININOGEN). Factor XIa then activates factor IX to factor IXa in the presence of calcium.
Laboratory tests for evaluating the individual's clotting mechanism.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C.
Activated form of factor IX. This activation can take place via the intrinsic pathway by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X.
Agents that cause clotting.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III.
Activated form of factor V. It is an essential cofactor for the activation of prothrombin catalyzed by factor Xa.
Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
Activated form of factor VIII. The B-domain of factor VIII is proteolytically cleaved by thrombin to form factor VIIIa. Factor VIIIa exists as a non-covalent dimer in a metal-linked (probably calcium) complex and functions as a cofactor in the enzymatic activation of factor X by factor IXa. Factor VIIIa is similar in structure and generation to factor Va.
Found in various tissues, particularly in four blood-clotting proteins including prothrombin, in kidney protein, in bone protein, and in the protein present in various ectopic calcifications.
A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
Transglutaminases catalyze cross-linking of proteins at a GLUTAMINE in one chain with LYSINE in another chain. They include keratinocyte transglutaminase (TGM1 or TGK), tissue transglutaminase (TGM2 or TGC), plasma transglutaminase involved with coagulation (FACTOR XIII and FACTOR XIIIa), hair follicle transglutaminase, and prostate transglutaminase. Although structures differ, they share an active site (YGQCW) and strict CALCIUM dependence.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
A family of ark shell mollusks, in the class BIVALVIA. They have soft bodies with platelike GILLS enclosed within two shells hinged together.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
Agents that prevent clotting.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A nutritional condition produced by a deficiency of VITAMIN K in the diet, characterized by an increased tendency to hemorrhage (HEMORRHAGIC DISORDERS). Such bleeding episodes may be particularly severe in newborn infants. (From Cecil Textbook of Medicine, 19th ed, p1182)
Amidines substituted with a benzene group. Benzamidine and its derivatives are known as peptidase inhibitors.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
An absence or reduced level of blood coagulation factor XII. It normally occurs in the absence of patient or family history of hemorrhagic disorders and is marked by prolonged clotting time.
The natural enzymatic dissolution of FIBRIN.
Activated form of factor XII. In the initial event in the intrinsic pathway of blood coagulation, kallikrein (with cofactor HIGH MOLECULAR WEIGHT KININOGEN) cleaves factor XII to XIIa. Factor XIIa is then further cleaved by kallikrein, plasmin, and trypsin to yield smaller factor XII fragments (Hageman-Factor fragments). These fragments increase the activity of prekallikrein to kallikrein but decrease the procoagulant activity of factor XII.
The time required by whole blood to produce a visible clot.
The rate dynamics in chemical or physical systems.
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
Hemorrhagic and thrombotic disorders that occur as a consequence of inherited abnormalities in blood coagulation.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
A hereditary deficiency of blood coagulation factor XI (also known as plasma thromboplastin antecedent or PTA or antihemophilic factor C) resulting in a systemic blood-clotting defect called hemophilia C or Rosenthal's syndrome, that may resemble classical hemophilia.
Proteins prepared by recombinant DNA technology.
A deficiency of blood coagulation FACTOR XIII or fibrin stabilizing factor (FSF) that prevents blood clot formation and results in a clinical hemorrhagic diathesis.
Hemorrhagic and thrombotic disorders resulting from abnormalities or deficiencies of coagulation proteins.
Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Physiologically inactive substances that can be converted to active enzymes.
Formation and development of a thrombus or blood clot in the blood vessel.
Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Activated form of FACTOR XIII, a transglutaminase, which stabilizes the formation of the fibrin polymer (clot) culminating the blood coagulation cascade.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Any liquid used to replace blood plasma, usually a saline solution, often with serum albumins, dextrans or other preparations. These substances do not enhance the oxygen- carrying capacity of blood, but merely replace the volume. They are also used to treat dehydration.
Blood coagulation disorder usually inherited as an autosomal recessive trait, though it can be acquired. It is characterized by defective activity in both the intrinsic and extrinsic pathways, impaired thromboplastin time, and impaired prothrombin consumption.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Absence or reduced levels of PROTHROMBIN in the blood.
The most common mineral of a group of hydrated aluminum silicates, approximately H2Al2Si2O8-H2O. It is prepared for pharmaceutical and medicinal purposes by levigating with water to remove sand, etc. (From Merck Index, 11th ed) The name is derived from Kao-ling (Chinese: "high ridge"), the original site. (From Grant & Hackh's Chemical Dictionary, 5th ed)
A deficiency of blood coagulation factor V (known as proaccelerin or accelerator globulin or labile factor) leading to a rare hemorrhagic tendency known as Owren's disease or parahemophilia. It varies greatly in severity. Factor V deficiency is an autosomal recessive trait. (Dorland, 27th ed)
The sum of the weight of all the atoms in a molecule.
An autosomal recessive characteristic or a coagulation disorder acquired in association with VITAMIN K DEFICIENCY. FACTOR VII is a Vitamin K dependent glycoprotein essential to the extrinsic pathway of coagulation.
A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease.
The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.
A cell surface glycoprotein of endothelial cells that binds thrombin and serves as a cofactor in the activation of protein C and its regulation of blood coagulation.
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
The degree of similarity between sequences of amino acids. This information is useful for the analyzing genetic relatedness of proteins and species.
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
Bleeding or escape of blood from a vessel.
Enzymes that catalyze the joining of two molecules by the formation of a carbon-carbon bond. These are the carboxylating enzymes and are mostly biotinyl-proteins. EC 6.4.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
Proteins obtained from species of REPTILES.
A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin.
A method of tissue ablation and bleeding control that uses ARGON plasma (ionized argon gas) to deliver a current of thermocoagulating energy to the area of tissue to be coagulated.
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.
Compounds and molecular complexes that consist of very large numbers of atoms and are generally over 500 kDa in size. In biological systems macromolecular substances usually can be visualized using ELECTRON MICROSCOPY and are distinguished from ORGANELLES by the lack of a membrane structure.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC, TISSUE KALLIKREIN (EC, and PROSTATE-SPECIFIC ANTIGEN (EC
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Endogenous peptides present in most body fluids. Certain enzymes convert them to active KININS which are involved in inflammation, blood clotting, complement reactions, etc. Kininogens belong to the cystatin superfamily. They are cysteine proteinase inhibitors. HIGH-MOLECULAR-WEIGHT KININOGEN; (HMWK); is split by plasma kallikrein to produce BRADYKININ. LOW-MOLECULAR-WEIGHT KININOGEN; (LMWK); is split by tissue kallikrein to produce KALLIDIN.
Venoms from snakes of the subfamily Crotalinae or pit vipers, found mostly in the Americas. They include the rattlesnake, cottonmouth, fer-de-lance, bushmaster, and American copperhead. Their venoms contain nontoxic proteins, cardio-, hemo-, cyto-, and neurotoxins, and many enzymes, especially phospholipases A. Many of the toxins have been characterized.
Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes.
A thrombin receptor subtype that couples to HETEROTRIMERIC GTP-BINDING PROTEINS resulting in the activation of a variety of signaling mechanisms including decreased intracellular CYCLIC AMP, increased TYPE C PHOSPHOLIPASES and increased PHOSPHOLIPASE A2.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
A deficiency or absence of FIBRINOGEN in the blood.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
Established cell cultures that have the potential to propagate indefinitely.
Solutions or mixtures of toxic and nontoxic substances elaborated by snake (Ophidia) salivary glands for the purpose of killing prey or disabling predators and delivered by grooved or hollow fangs. They usually contain enzymes, toxins, and other factors.
A family of proteinase-activated receptors that are specific for THROMBIN. They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. Activation of thrombin receptors occurs through the proteolytic action of THROMBIN, which cleaves the N-terminal peptide from the receptor to reveal a new N-terminal peptide that is a cryptic ligand for the receptor. The receptors signal through HETEROTRIMERIC GTP-BINDING PROTEINS. Small synthetic peptides that contain the unmasked N-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.
Inflammation of a vein associated with a blood clot (THROMBUS).
An arthropod subclass (Xiphosura) comprising the North American (Limulus) and Asiatic (Tachypleus) genera of horseshoe crabs.
Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent.
Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia.
Elements of limited time intervals, contributing to particular results or situations.
A family of snakes comprising three subfamilies: Azemiopinae (the mountain viper, the sole member of this subfamily), Viperinae (true vipers), and Crotalinae (pit vipers). They are widespread throughout the world, being found in the United States, Central and South America, Europe, Asia and Africa. Their venoms act on the blood (hemotoxic) as compared to the venom of elapids which act on the nervous system (neurotoxic). (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, pp333-36)
The use of green light-producing LASERS to stop bleeding. The green light is selectively absorbed by HEMOGLOBIN, thus triggering BLOOD COAGULATION.
A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.
A genus of snakes of the family VIPERIDAE. It is distributed in West Pakistan, most of India, Burma, Ceylon, Thailand, southeast China, Taiwan, and a few islands of Indonesia. It hisses loudly when disturbed and strikes with great force and speed. Very prolific, it gives birth to 20-60 young. This viper is the leading cause of snakebite in India and Burma. (Moore: Poisonous Snakes of the World, 1980, p127)
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
Proteins synthesized by organisms belonging to the phylum ARTHROPODA. Included in this heading are proteins from the subdivisions ARACHNIDA; CRUSTACEA; and HORSESHOE CRABS. Note that a separate heading for INSECT PROTEINS is listed under this heading.
The formation or presence of a blood clot (THROMBUS) within a vein.
Hormones produced by invertebrates, usually insects, mollusks, annelids, and helminths.
Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.
Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES.
A 3.5 per cent colloidal solution containing urea-cross-linked polymerized peptides. It has a molecular weight of approximately 35,000 and is prepared from gelatin and electrolytes. The polymeric solution is used as a plasma expander.
Procedures using an electrically heated wire or scalpel to treat hemorrhage (e.g., bleeding ulcers) and to ablate tumors, mucosal lesions, and refractory arrhythmias. It is different from ELECTROSURGERY which is used more for cutting tissue than destroying and in which the patient is part of the electric circuit.
Venoms from SNAKES of the viperid family. They tend to be less toxic than elapid or hydrophid venoms and act mainly on the vascular system, interfering with coagulation and capillary membrane integrity and are highly cytotoxic. They contain large amounts of several enzymes, other factors, and some toxins.
The process whereby PLATELETS adhere to something other than platelets, e.g., COLLAGEN; BASEMENT MEMBRANE; MICROFIBRILS; or other "foreign" surfaces.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
OXIDOREDUCTASES which mediate vitamin K metabolism by converting inactive vitamin K 2,3-epoxide to active vitamin K.
A peptidohydrolytic enzyme that is formed from PREKALLIKREIN by FACTOR XIIA. It activates FACTOR XII; FACTOR VII; and PLASMINOGEN. It is selective for both ARGININE and to a lesser extent LYSINE bonds. EC
Limbless REPTILES of the suborder Serpentes.
A foul-smelling diamine formed by bacterial decarboxylation of lysine.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.
A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair.
A plant genus of the family MORACEAE. Puag-haad extract, from A. lakoocha, contains STILBENES and related 4-substituted RESORCINOLS.
A genus of snakes of the family VIPERIDAE. About 30 species are currently recognized, found in southeast Asia and adjacent island chains. The Okinawa habu frequently enters dwellings in search of rats and mice; the Chinese habu is often found in suburban and agricultural areas. They are quite irritable. (Moore: Poisonous Snakes of the World, 1980, p136)
A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
GLYCOSPHINGOLIPIDS with a sulfate group esterified to one of the sugar groups.
A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.
A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
A salt used to replenish calcium levels, as an acid-producing diuretic, and as an antidote for magnesium poisoning.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
Hemorrhage caused by vitamin K deficiency.
An absence or deficiency in PROTEIN C which leads to impaired regulation of blood coagulation. It is associated with an increased risk of severe or premature thrombosis. (Stedman's Med. Dict., 26th ed.)
Loss of blood during a surgical procedure.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.
Colorless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into colored compounds; used in biochemical assays and in diagnosis as indicators, especially in the form of enzyme substrates. Synonym: chromogens (not to be confused with pigment-synthesizing bacteria also called chromogens).
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
An order of nematodes of the subclass SECERNENTEA. Characteristics include an H-shaped excretory system with two subventral glands.
A fused four ring compound occurring free or combined in galls. Isolated from the kino of Eucalyptus maculata Hook and E. Hemipholia F. Muell. Activates Factor XII of the blood clotting system which also causes kinin release; used in research and as a dye.
A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.
CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.
A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
Peptides composed of between two and twelve amino acids.
A family of soil bacteria. It also includes some parasitic forms.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion.
Chemical groups containing the covalent disulfide bonds -S-S-. The sulfur atoms can be bound to inorganic or organic moieties.
The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.
Arginine derivative which is a substrate for many proteolytic enzymes. As a substrate for the esterase from the first component of complement, it inhibits the action of C(l) on C(4).
Antibodies produced by a single clone of cells.
A class of receptors that are activated by the action of PROTEINASES. The most notable examples are the THROMBIN RECEPTORS. The receptors contain cryptic ligands that are exposed upon the selective proteolysis of specific N-terminal cleavage sites.
A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS.
Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
An infant born at or after 42 weeks of gestation.
Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.
Poisonous animal secretions forming fluid mixtures of many different enzymes, toxins, and other substances. These substances are produced in specialized glands and secreted through specialized delivery systems (nematocysts, spines, fangs, etc.) for disabling prey or predator.
Substances that display the physical properties of ELASTICITY and VISCOSITY. The dual-nature of these substances causes them to resist applied forces in a time-dependent manner.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
A malignant tumor originating from the endothelial cells of lymphatic vessels. Most lymphangiosarcomas arise in an arm secondary to radical mastectomy but they sometimes complicate idiopathic lymphedema. The lymphedema has usually been present for 6 to 10 years before malignant changes develop. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
A G-protein-coupled, proteinase-activated receptor that is expressed in a variety of tissues including ENDOTHELIUM; LEUKOCYTES; and the GASTROINTESTINAL TRACT. The receptor is activated by TRYPSIN, which cleaves off the N-terminal peptide from the receptor. The new N-terminal peptide is a cryptic ligand for the receptor. The uncleaved receptor can also be activated by the N-terminal peptide present on the activated THROMBIN RECEPTOR and by small synthetic peptides that contain the unmasked N-terminal sequence.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).

Evidence suggesting the regulation of a coagulation factor levels in rabbits by a transferable plasma agent. (1/1153)

New Zealand white rabbits were given 30 ml of goat serum intravenously. This procedure resulted in an immediate decrease in platelet count, fibrinogen, and levels of coagulation factors II, V, VII, and X, due to consumption coagulopathy. These factors returned toward baseline levels approximately 12 hr after the injection. Plasma from rabbits who had received goat serum 48 hr previously (donor rabbits) was injected into recipient rabbits. This procedure resulted in a slight rise in the level of coagulation factor II (range, 20%-30%) and a significant rise in factors V (35%-75%), VII (35%-235%), and X (35%-75%) in the recipients. When plasma from control donor rabbits who had not received goat serum was injected into recipients, there was no change in these coagulation factors. It is postulated that the reduction in coagulation factor levels in donor rabbits induces a "coagulopoietin" for each factor or one "coagulopoietin" for all factors which stimulates increased synthesis and/or release of these factors in recipient rabbits.  (+info)

The induction of macrophage spreading: role of coagulation factors and the complement system. (2/1153)

Unstimulated mouse peritoneal macrophages, attached to either glass or plastic substrates, responded to factors generated in serum and plasma by spreading and increasing their apparent surface area up to eightfold. Two distinct and dissociable systems were involved. The first appears related to the distinct and dissociable systems were involved. The first appears related to the contact phase of blood coagulation. It is activated by glass and not plastic surfaces, depleted by kaolin adsorption, and inhibited by soybean trypsin inhibitor. In contrast, a separate complement-dependent system can be generated in kaolin-adsorbed plasma. Activation of the complement system can occur either by the alternate or classical pathways and generates a relatively small effector molecule which is dialyzable. These factors presumably influencing the surface membrane and underlying structures may explain the rapid spreading of activated macrophages observed after both infections and chemical peritoneal inflammatory agents.  (+info)

Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. (3/1153)

Blocking protein C binding to the endothelial cell protein C receptor (EPCR) on the endothelium is known to reduce protein C activation rates. Now we isolate human EPCR and thrombomodulin (TM) and reconstitute them into phosphatidylcholine vesicles. The EPCR increases protein C activation rates in a concentration-dependent fashion that does not saturate at 14 EPCR molecules/TM. Without EPCR, the protein C concentration dependence fits a single class of sites (Km = 2.17 +/- 0.13 microM). With EPCR, two classes of sites are apparent (Km = 20 +/- 15 nM and Km = 3.2 +/- 1.7 microM). Increasing the EPCR concentration at a constant TM concentration increases the percentage of high affinity sites. Holding the TM:EPCR ratio constant while decreasing the density of these proteins results in a decrease in the EPCR enhancement of protein C activation, suggesting that there is little affinity of the EPCR for TM. Negatively charged phospholipids also enhance protein C activation. EPCR acceleration of protein C activation is blocked by anti-EPCR antibodies, but not by annexin V, whereas the reverse is true with negatively charged phospholipids. Human umbilical cord endothelium expresses approximately 7 times more EPCR than TM. Anti-EPCR antibody reduces protein C activation rates 7-fold over these cells, whereas annexin V is ineffective, indicating that EPCR rather than negatively charged phospholipid provide the surface for protein C activation. EPCR expression varies dramatically among vascular beds. The present results indicate that the EPCR concentration will determine the effectiveness of the protein C activation complex.  (+info)

Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues. (4/1153)

Human factor VIII/von Willebrand factor protein containing 120 +/- 12 nmol of sialic acid and 135 +/- 13 nmol of galactose/mg of protein was digested with neuraminidase. The affinity of native factor VIII/von Willebrand factor and its asialo form for the hepatic lectin that specifically binds asialoglycoproteins was assessed from in vitro binding experiments. Native factor VIII/von Willebrand factor exhibited negligible affinity while binding of the asialo derivative was comparable to that observed for asialo-alpha1-acid glycoprotein. Incubation of asialo-factor VIII/von Willebrand factor with Streptococcus pneumoniae beta-galactosidase removed only 62% of the galactose but abolished binding to the purified hepatic lectin. When the asialo derivative was incubated with purified beta-D-galactoside alpha2 leads to 6 sialyltransferase and CMP-[14C]NeuAc, only 61% of the galactose incorporated [14C]NeuAc. From the known specificites of these enzymes, it is concluded that galactose residues important in lectin binding are present in a terminal Gal/beta1 leads to 4GlcNAc sequence on asialo-factor VIII/von Willebrand factor. The relative ristocetin-induced platelet aggregating activity of native, asialo-, and agalacto-factor VIII/von Willebrand factor was 100:38:12, respectively, while procoagulant activity was 100:100:103.  (+info)

Unexpected crucial role of residue 225 in serine proteases. (5/1153)

Residue 225 in serine proteases of the chymotrypsin family is Pro or Tyr in more than 95% of nearly 300 available sequences. Proteases with Y225 (like some blood coagulation and complement factors) are almost exclusively found in vertebrates, whereas proteases with P225 (like degradative enzymes) are present from bacteria to human. Saturation mutagenesis of Y225 in thrombin shows that residue 225 affects ligand recognition up to 60,000-fold. With the exception of Tyr and Phe, all residues are associated with comparable or greatly reduced catalytic activity relative to Pro. The crystal structures of three mutants that differ widely in catalytic activity (Y225F, Y225P, and Y225I) show that although residue 225 makes no contact with substrate, it drastically influences the shape of the water channel around the primary specificity site. The activity profiles obtained for thrombin also suggest that the conversion of Pro to Tyr or Phe documented in the vertebrates occurred through Ser and was driven by a significant gain (up to 50-fold) in catalytic activity. In fact, Ser and Phe are documented in 4% of serine proteases, which together with Pro and Tyr account for almost the entire distribution of residues at position 225. The unexpected crucial role of residue 225 in serine proteases explains the evolutionary selection of residues at this position and shows that the structural determinants of protease activity and specificity are more complex than currently believed. These findings have broad implications in the rational design of enzymes with enhanced catalytic properties.  (+info)

Inflammation, sepsis, and coagulation. (6/1153)

The molecular links between inflammation and coagulation are unquestioned. Inflammation promotes coagulation by leading to intravascular tissue factor expression, eliciting the expression of leukocyte adhesion molecules on the intravascular cell surfaces, and down regulating the fibrinolytic and protein C anticoagulant pathways. Thrombin, in turn, can promote inflammatory responses. This creates a cycle that logically progresses to vascular injury as occurs in septic shock. Most complex systems are regulated by product inhibition. This inflammation-coagulation cycle seems to follow this same principle with the protein C pathway serving as the regulatory mechanism. The molecular basis by which the protein C pathway functions as an anticoagulant is relatively well established compared to the mechanisms involved in regulating inflammation. As one approach to identifying the mechanisms involved in regulating inflammation, we set out to identify novel receptors that could modulate the specificity of APC in a manner analogous to the mechanisms by which thrombomodulin modulates thrombin specificity. This approach led to the identification of an endothelial cell protein C receptor (EPCR). To understand the mechanism, we obtained a crystal structure of APC (lacking the Gla domain). The crystal structure reveals a deep groove in a location analogous to anion binding exosite 1 of thrombin, the location of interaction for thrombomodulin, platelet thrombin receptor and fibrinogen. Thrombomodulin blocks the activation of platelets and fibrinogen without blocking reactivity with chromogenic substrates or inhibitors. Similarly, in solution, EPCR blocks factor Va inactivation without modulating reactivity with protease inhibitors. Thus, these endothelial cell receptors for the protein C system share many properties in common including the ability to be modulated by inflammatory cytokines. Current studies seek to identify the substrate for the APC-EPCR complex as the next step in elucidating the mechanisms by which the protein C pathway modulates the response to injury and inflammation.  (+info)

Regulation and functions of the protein C anticoagulant pathway. (7/1153)

The protein C pathway plays a critical role in the negative regulation of the blood clotting process. We recently identified an endothelial cell receptor for protein C/activated protein C (APC). The receptor is localized almost exclusively on endothelial cells of large vessels and is present at only trace levels or indeed absent from capillaries in most tissues. Patients with sepsis or lupus erythematosus exhibit elevated levels of plasma EPCR which migrates on gels as a single band and is fully capable of binding protein C/APC. There is no correlation with thrombomodulin levels, probably due to different vascular localizations and/or cellular release mechanisms. To understand the mechanisms by which EPCR plasma levels are elevated, we examined EPCR mRNA expression in a rat endotoxin shock model. The EPCR mRNA gene exhibited an early immediate gene response to endotoxin with the mRNA levels increasing nearly 4 fold in the first 3-6 hrs, before returning toward baseline. Plasma levels of EPCR also rose about 4 fold with little change in tissue EPCR levels. Both processes were markedly attenuated by hirudin suggesting that thrombin was responsible for increases in mRNA and plasma EPCR levels. At the level of mRNA, the induction is mediated by a thrombin response element in the 5' flanking region of the gene. Direct thrombin infusion and cell culture experiments support this contention. On endothelium, thrombin is capable of releasing cell surface EPCR and this process is blocked by the metalloproteinase inhibitor orthophenanthroline. Taken together these studies indicate that elevation in soluble plasma EPCR reflects endothelial cell activation in the larger vessels and is likely to be an indication of local thrombin generation near these vessel surfaces.  (+info)

Inhibitory effect of sulfur-containing compounds in Scorodocarpus borneensis Becc. on the aggregation of rabbit platelets. (8/1153)

The inhibitory effects of three pure compounds isolated from wood garlic, 2,4,5-trithiahexane (I), 2,4,5,7-tetrathiaoctane (II), and 2,4,5,7-tetrathiaoctane 2,2-dioxide (III), on rabbit platelet aggregation induced by collagen, arachidonic acid, U46619, ADP (adenosine 5'-diphosphate), PAF (platelet aggregating factor), and thrombin were studied in vitro. The anti-aggregating activity of 2,4,5,7-tetrathiaoctane 4,4-dioxide (IV) was also measured with collagen and arachidonic acid. I, II, III, and IV inhibited the platelet aggregation induced by all tested agonists. I, II, and III exhibited a stronger inhibitory effect against the thrombin-induced aggregation of GFP (gel-filtered platelets) than against the aggregation induced by the other agonists. Notably, the IC50 value for III was 4 microM, which is approximately 2.5 times stronger than MATS (methyl allyl trisulfide), a major anti-platelet compound isolated from garlic. In inhibiting collagen-induced aggregation, II was as potent as MATS and aspirin, with a marked disaggregation effect on the secondary aggregation by arachidonic acid, at the rate of 47.05%/min at a concentration of 10(-4) M. I, II, and III also suppressed U46619-induced aggregation. These results suggest that sulfur-containing compounds in wood garlic not only inhibit arachidonic acid metabolism but also suppress aggregation in association with the function of the platelet plasma membrane.  (+info)

Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer with a high mortality rate as it responds poorly to standard therapeutic interventions. Our recent studies showed that expression of endothelial cell protein C receptor (EPCR) in MPM cells suppresses tumorigenicity. The present study was aimed to investigate the mechanism by which EPCR suppresses MPM tumor growth and evaluate whether EPCR gene therapy could suppress the progression of MPM in a mouse model of MPM. Measurement of cytokines from the pleural lavage showed that mice implanted with MPM cells expressing EPCR had elevated levels of IFNγ and TNFα compared to mice implanted with MPM cells lacking EPCR. In vitro studies demonstrated that EPCR expression renders MPM cells highly susceptible to IFNγ + TNFα-induced apoptosis. Intrapleural injection of Ad.EPCR into mice with an established MPM originating from MPM cells lacking EPCR reduced the progression of tumor growth. Ad.EPCR treatment elicited recruitment of ...
[107 Pages Report] Check for Discount on Global Coagulation Factor Concentrate Market Professional Survey Report 2017 report by QYResearch Group. This report studies Coagulation Factor Concentrate in Global market, especially...
There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) on rivaroxaban or apixaban. We investigated the effectiveness of PCCs given for the management of MBEs in patients on rivaroxaban or apixaban. Between 1 January 2014 and 1 October 2016, we prospectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs. The effectiveness of PCCs was assessed by using the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria for the assessment of the effectiveness of major bleeding management. The safety outcomes were thromboembolic events and all-cause mortality within 30 days after treatment with PCCs. A total of 84 patients received PCCs for the reversal of rivaroxaban or apixaban due to a MBE. PCCs were given at a median (interquartile range) dose of 2000 IU (1500-2000 ...
Mast cells (MCs) are immune sentinels, but whether they also function as antigen-presenting cells (APCs) remains elusive. Using mouse models of MC deficiency, we report on MC-dependent recruitment and activation of multiple T cell subsets to the skin and draining lymph nodes (DLNs) during dengue virus (DENV) infection. Newly recruited and locally proliferating γδ T cells were the first T cell subset to respond to MC-driven inflammation, and their production of IFN-γ was MC dependent. MC-γδ T cell conjugates were observed consistently in infected peripheral tissues, suggesting a new role for MCs as nonconventional APCs for γδ T cells. MC-dependent γδ T cell activation and proliferation during DENV infection required T cell receptor (TCR) signaling and the nonconventional antigen presentation molecule endothelial cell protein C receptor (EPCR) on MCs. γδ T cells, not previously implicated in DENV host defense, killed infected targeted DCs and contributed to the clearance of DENV in ...
Mast cells (MCs) are immune sentinels, but whether they also function as antigen-presenting cells (APCs) remains elusive. Using mouse models of MC deficiency, we report on MC-dependent recruitment and activation of multiple T cell subsets to the skin and draining lymph nodes (DLNs) during dengue virus (DENV) infection. Newly recruited and locally proliferating γδ T cells were the first T cell subset to respond to MC-driven inflammation, and their production of IFN-γ was MC dependent. MC-γδ T cell conjugates were observed consistently in infected peripheral tissues, suggesting a new role for MCs as nonconventional APCs for γδ T cells. MC-dependent γδ T cell activation and proliferation during DENV infection required T cell receptor (TCR) signaling and the nonconventional antigen presentation molecule endothelial cell protein C receptor (EPCR) on MCs. γδ T cells, not previously implicated in DENV host defense, killed infected targeted DCs and contributed to the clearance of DENV in ...
Mast cells (MCs) are immune sentinels, but whether they also function as antigen-presenting cells (APCs) remains elusive. Using mouse models of MC deficiency, we report on MC-dependent recruitment and activation of multiple T cell subsets to the skin and draining lymph nodes (DLNs) during dengue virus (DENV) infection. Newly recruited and locally proliferating γδ T cells were the first T cell subset to respond to MC-driven inflammation, and their production of IFN-γ was MC dependent. MC-γδ T cell conjugates were observed consistently in infected peripheral tissues, suggesting a new role for MCs as nonconventional APCs for γδ T cells. MC-dependent γδ T cell activation and proliferation during DENV infection required T cell receptor (TCR) signaling and the nonconventional antigen presentation molecule endothelial cell protein C receptor (EPCR) on MCs. γδ T cells, not previously implicated in DENV host defense, killed infected targeted DCs and contributed to the clearance of DENV in ...
Several proteins already known or implicated as metalloprotease-shed proteins were identified in this study using two different cell systems. These include amyloid A4 protein, IL-1R-2, IL-6R-1, l-selectin, M-CSFR, SorLA, AXLr, and endothelial cell protein C receptor (7, 8, 12, 13, 22-27). Thus, this proteomic technique was validated as a method that can be applied in studies of protein shedding. In addition, this study implicated a number of additional proteins as being shed by metalloproteases, including LDLr, SHPS-1, and Jagged 1. TACE was shown to be the responsible protease in the case of the LDLr and some of the previously identified shed proteins (e.g. AXLr and hybrid receptor SorLA) for which the sheddase had not been determined.. LDLr is known as a cell-surface receptor that binds to LDL, the major cholesterol-carrying lipoprotein in plasma, and transports LDL into cells by endocytosis (28). Other LDLr gene family proteins, including SorLA (see Fig. 4, a shed protein found here to be ...
Professional guide for Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]. Includes: pharmacology, pharmacokinetics, contraindications, interactions, adverse reactions and more.
The Global Prothrombin Complex Concentrates Market is likely to gain traction due to the significant drop in demand for its counterpart fresh frozen plasma (FFP). PCC is available easily due to its lack of blood group specificity.
Proteinase-activated receptor 1 (PAR1) also known as Protease-activated receptor 1 or coagulation factor II (thrombin) receptor is a protein that in humans is encoded by the F2R gene. PAR1 is a G protein-coupled receptor involved in the regulation of thrombotic response. Proteolytic cleavage leads to the activation of the receptor. PAR-1 has multifaceted effects and plays a key role in mediating the interplay between coagulation and inflammation, which is important in the pathogenesis of inflammatory and fibrotic lung diseases. It is involved both in disruption and maintaining of endothelial barrier integrity, through interaction with either thrombin or activated protein C, respectively. Several selective antagonists for the PAR1 receptor have been developed, for use as anti-clotting agents for the treatment of heart disease. SCH-530,348 SCH530348 has been recently shown to attenuate the neutrophilic inflammatory response to Streptococcus pneumoniae by reducing levels of pro-inflamamtory ...
PAR-3 activates coagulation factor II thrombin receptor like 2 (F2RL2) in a dose-dependent manner (Figure). Available assay modes and other details are shown.
Fausto Biancari, Vito G Ruggieri, Andrea Perrotti, Riccardo Gherli, Till Demal, Ilaria Franzese, Magnus Dalén, Giuseppe Santarpino, Antonino S Rubino, Daniele Maselli, Antonio Salsano, Francesco Nicolini, Matteo Saccocci, Giuseppe Gatti, Stefano Rosato, Paola DErrigo, Eeva-Maija Kinnunen, Marisa De Feo, Tuomas Tauriainen, Francesco ...
Consider [[Prothrombin Complex Concentrate]] (PCC): 50 IU/kg IV bolus,ref,Eerenberg ES, et al. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011 Sep 6.,/ref ...
F2rl1 - F2rl1 (untagged) - Mouse coagulation factor II (thrombin) receptor-like 1 (cDNA clone MGC:29183 IMAGE:5006769), (10ug) available for purchase from OriGene - Your Gene Company.
Medical Acupuncture Program An Evidence-Based Approach, McMaster University Program Chair: Dr. K. Trinh, MD, MSc., FCFP, FRSS Diploma in Sports Medicine Chair, M.D. Program Admissions Acupuncture is a system of diagnosis and treatment. The diagnosis is based on a comprehensive Chinese theory of energy balance. The treatment involves insertion of small solid needles into precise anatomical sites in the body to produce therapeutic effects.
Fingerprint Dive into the research topics of Endothelial cell protein C receptor (EPCR) gene exon III, 23 BP insertion mutation in Turkish Cypriots. Together they form a unique fingerprint. ...
EPCR signaling can decrease inflammation. APC binding to EPCR rescues baboons from E. coli sepsis.12 EPCR has also cardioprotective role in lipopolyscharide-induced endotoxemia in mice.14 In addition to the cell-surface EPCR, soluble EPCR lacking the transmembrane helix of native EPCR interacts with the integrin CD11b/CD18 (Mac-1) (αMβ2) (CR3) on leukocytes (Figure 1), suggesting that binding of soluble EPCR to Mac-1 might regulate leukocytes adhesion.15 Proteinase-3 (PR3), a serine protease with elastase-like properties stored in granules of neutrophils, binds both Mac-1 and soluble EPCR which may be implicated in APC mediated signaling and activation of PC on leukocytes, because soluble EPCR:PR3 complexes bind both APC and PC.15. Recent evidence indicates that EPCR is expressed on different cells beyond aortic endothelial cells. For example, EPCR is expressed on the surface of monocytes, CD56+ natural killer cells, neutrophils and eosinophils16-18, immature hematopoietic stem cells,19 brain ...
TY - JOUR. T1 - Genetics of the thrombomodulin-endothelial cell protein C receptor system and the risk of early-onset ischemic stroke. AU - Cole, John W.. AU - Xu, Huichun. AU - Ryan, Kathleen. AU - Jaworek, Thomas. AU - Dueker, Nicole. AU - McArdle, Patrick. AU - Gaynor, Brady. AU - Cheng, Yu Ching. AU - OConnell, Jeffrey. AU - Bevan, Steve. AU - Malik, Rainer. AU - Ahmed, Naveed Uddin. AU - Amouyel, Philippe. AU - Anjum, Sheraz. AU - Bis, Joshua C.. AU - Crosslin, David. AU - Danesh, John. AU - Engelter, Stefan T.. AU - Fornage, Myriam. AU - Frossard, Philippe. AU - Gieger, Christian. AU - Giese, Anne Katrin. AU - Grond-Ginsbach, Caspar. AU - Ho, Weang Kee. AU - Holliday, Elizabeth. AU - Hopewell, Jemma. AU - Hussain, M.. AU - Iqbal, W.. AU - Jabeen, S.. AU - Jannes, Jim. AU - Kamal, Ayeesha. AU - Kamatani, Yoichiro. AU - Kanse, Sandip. AU - Kloss, Manja. AU - Lathrop, Mark. AU - Leys, Didier. AU - Lindgren, Arne. AU - LongstrethJr, W. T.. AU - Mahmood, Khalid. AU - Meisinger, Christa. AU - ...
Prothrombin complex concentrate (PCC) is a drug that contains a source of proteins involved in the human blood clotting process. Patients medicated with vitamin K antagonists (blood thinning drug) have low blood levels of these important blood clotting proteins. Therefore these patients will be at increased risk of spontaneous and traumatic bleeding events. Also, when these patients experience a bleeding event, this will lead to progressive loss of these important blood clotting proteins. This process causes a vicious circle, thereby increasing risks of illness and death.. In the present Cochrane systematic review, we assessed the benefits and harms of prothrombin complex concentrate in vitamin K antagonist-treated bleeding and non-bleeding patients who are undertaking acute surgical intervention. We searched the databases until 1 May 2013. We identified four randomized trials (453 participants) involving neurological and cardiac surgical settings, as well as medical reversal of vitamin ...
Uniquely amongst vitamin K-dependent coagulation proteins, protein C interacts via its Gla domain both with a receptor, the endothelial cell protein C receptor (EPCR), and with phospholipids. We have studied naturally occurring and recombinant protein C Gla domain variants for soluble (s)EPCR binding, cell surface activation to activated protein C (APC) by the thrombin-thrombomodulin complex, and phospholipid dependent factor Va (FVa) inactivation by APC, to establish if these functions are concordant. Wild-type protein C binding to sEPCR was characterized with surface plasmon resonance to have an association rate constant of 5.23 x 10(5) m(-1).s(-1), a dissociation rate constant of 7.61 x 10(-2) s(-1) and equilibrium binding constant (K(D)) of 147 nm. It was activated by thrombin over endothelial cells with a K(m) of 213 nm and once activated to APC, rapidly inactivated FVa. Each of these interactions was dramatically reduced for variants causing gross Gla domain misfolding (R-1L, R-1C, E16D ...
The endothelial protein C receptor (EPCR) is expressed by trophoblast cells. Mid-gestation pregnancy loss is described in animals with a haemochorial placenta lacking EPCR. The A6936G allele of the EPCR gene (PROCR) may be associated with lower EPCR densities on trophoblasts, but data are lacking for its effect on the risk of pregnancy loss in humans. A 1:2 case-control study on unexplained pregnancy loss was nested in the NOHA First cohort: 3,218 case couples and 6,436 control couples were studied for PROCR A6936G, coagulation factor V gene (F5) G1691A and coagulation factor II gene (F2) G20210A polymorphisms. Ethnicity and time of pregnancy loss defined through biometry-based gestational ages (embryonic loss | 10(th) week | or = foetal loss) were analysed. The PROCR A6936G allele, in mothers and fathers, was associated only with foetal loss in both Europeans and non-Europeans. Increasing probability levels of carrying a homozygous child were increasingly associated with the risk of foetal demise. The
Background-Patients experiencing major bleeding while taking vitamin K antagonists (VKAs) require rapid VKA reversal. We performed a prospective clinical trial to compare non-activated four-factor prothrombin complex concentrate (4F-PCC) with plasma for urgent VKA reversal. Methods and Results-In this phase IIIb, multicenter, open-label, non-inferiority trial, non-surgical patients were randomized to 4F-PCC (containing coagulation factors II, VII, IX, X, and proteins C, S) or plasma. Primary analyses examined whether 4F-PCC was non-inferior to plasma for the co-primary endpoints of 24-hour hemostatic efficacy from start of infusion and INR correction (≤1.3) at 0.5 hours after end of infusion. The intent-to-treat-efficacy population comprised 202 patients (4F-PCC n=98; plasma n=104). Median (range) baseline INR was 3.90 (1.8-20.0) for the 4F-PCC group and 3.60 (1.9-38.9) for the plasma group. Effective hemostasis was achieved in 72.4% of patients receiving 4F-PCC versus 65.4% receiving plasma, ...
Background: Although endothelial cell protein C receptor (EPCR) gene Ser219Gly polymorphism has been associated with venous thromboembolism (VTE) susceptibility, no clear consensus has yet been reached. Objective and methods: A meta-analysis of 9,494 subjects from 13 individual studies was conducted to better elucidate the potential relationship between the EPCR gene Ser219Gly polymorphism and VTE. Pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were evaluated by using fixed or random effect models.Results: The current meta-analysis suggested that there was a significant association between EPCR gene Ser219Gly polymorphism and VTE under allelic (OR: 1.42, 95% CI: 1.21-1.66, P=1.30×10-5), recessive (OR: 2.02, 95% CI: 1.44-2.85, P=5.35×10-5), homozygous (OR: 2.24, 95% CI: 1.59-3.16, P=3.66×10-6), and additive genetic models (OR: 1.63, 95% CI: 1.30-2.04, P=2.24×10-5). Conclusions: EPCR gene Ser219Gly polymorphism was associated with an elevated risk of VTE and the Gly
Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis.
The management of bleeding patients on vitamin K antagonist (VKA) therapy is a common clinical challenge. Current American College of Chest Physician (ACCP) guidelines recommend the use of prothrombin complex concentrates (PCCs) for rapid reversal of VKA-induced coagulopathy.1. While efficacy and safety of PCC are well established for VKA reversal, a well-defined dosing strategy is still lacking.. Recently, we studied the effectiveness of a low fixed dose regimen of 1040 IU F IX PCC compared to variable dosing to counteract VKA associated emergency bleeding.2 This prospective study showed that low fixed PCC dose was non-inferior to variable dosing in terms of clinical outcome. In reaching the target INR, defined as INR less than 2, the fixed dose was non-inferior in patients with an initial INR below 7.5, but not in patients with a higher INR.. An important question from both a clinical and costing point of view is whether additional interventions were needed in the fixed dose cohort to reach ...
This page includes the following topics and synonyms: Prothrombin Complex Concentrate, Prothrombin Drug Combination, PCC, Beriplex, Octaplex, Kcentra, Cofact.
Three examples of human plasma-derived concentrates, intermediate-purity factors VIII and IX, and fibrinogen were spiked with tissue culture-grown human immunodeficiency virus type 1 (HIV-1) strain RF. All examples were freeze-dried and heated at 80 degrees C for 72 hours by using validated production process models. HIV-1 infectivity was measured by a syncytial infectivity assay in C8166 cells and then compared with levels determined by nested HIV polymerase chain reaction (PCR). The infectivity assay demonstrated a reduction index of at least 4.5 log10, while PCR showed an average 1.7 log10. Large amounts of HIV-1 RNA (10(5)) were still detectable by PCR in samples in which infectivity assays failed to detect any HIV-1. These data suggest that HIV-1 PCR levels do not parallel HIV-1 infectivity levels during virus-inactivation procedures involved in coagulation factor concentrate production. PCR was able to detect the RNA associated with inactivated HIV-1 particles in the factor concentrates, which
The protein encoded by this gene is a receptor for activated protein C, a serine protease activated by and involved in the blood coagulation pathway. The encoded protein is an N-glycosylated type I membrane protein that enhances the activation of protein C. Mutations in this gene have been associated with venous thromboembolism and myocardial infarction, as well as with late fetal loss during pregnancy. The encoded protein may also play a role in malarial infection and has been associated with cancer. [provided by RefSeq, Jul 2013 ...
Question about target INRs when treating coagulopathic patients with frozen plasma or prothrombin complex concentrate (PCC) Question: On page 36 of Bloody Easy 4: Blood Transfusions, Blood Alternatives and Transfusion Reactions. A Guide to Transfusion Medicine Fourth Edition (1), the threshold INR for plasma transfusion is greater than or equal to 1.8. On page 126, regarding the use of prothrombin complex concentrate (PCC) for emergency warfarin reversal, the threshold INR is greater than or equal to 1.5. Why is the INR threshold for plasma 1.8, and the threshold for PCCs 1.5? Shouldnt they be the same? Answer by Dr. Allison Collins, MD: Coagulation factors are at sufficient levels (30% of normal) for normal hemostasis at an INR of about 1.7 (2). The INR is a poor predictor of bleeding risk, particularly if only mildly elevated, and there is no good evidence for use of a target INR of 1.5 vs 1.8 for prevention or treatment of bleeding. INR reversal with plasma is not as effective as INR ...
Sales, means the sales volume of Human Prothrombin Complex Revenue, means the sales value of Human Prothrombin Complex This report studies sales (consumption) of Human Prothrombin Complex in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Baxter CSL Bayer Grifols Octapharma Shanghai RAAS Hualan Bio
Read chapter a17 of Goldfranks Toxicologic Emergencies, 11e online now, exclusively on AccessPharmacy. AccessPharmacy is a subscription-based resource from McGraw Hill that features trusted pharmacy content from the best minds in the field.
Results 45 patients were treated with PCC and included in the analysis. Mean patient age was 59.64 years, 42.2% were women and 57.77% men. The average dose was 1604 IU, the global survival after seven days was 73.33% and 35.55% had concomitant treatment with fibrinogen.. 11.11% of the patients had been treated with oral anticoagulants (OAT) prior to the emergency bleeding,. 48.89% had polytraumatic wounds,. 4.44% had thrombocytopenia secondary to hepatopathy,. 0% had haemophilia,. 75.55% had an active haemorrhage,. 68.89% underwent surgery, when the PCC was administered.. Quick time (s) (% // INR):. ...
Synonyms for Coagulation factors in Free Thesaurus. Antonyms for Coagulation factors. 2 synonyms for coagulation: clotting, curdling. What are synonyms for Coagulation factors?
[106 Pages Report] Check for Discount on Global Prothrombin Complex Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 report by Global Info Research. Market Overview The global Prothrombin Complex market size is expected...
When warfarin reversal must be accomplished rapidly, such as in cases of active bleeding or in preparation for an invasive procedure, multiple options exist, chief among them being fresh frozen plasma (FFP) and four factor prothrombin complex concentrate (4-PCC). Between those two options, the ACCP guidelines suggest (soft recommendation) 4-PCC over FFP. This was based on low level data (very small studies) showing more rapid INR reversal using the former. This study, which came out after publication of the ACCP guidelines, added further weight in favor of 4-PCC in patients deemed appropriate for rapid warfarin reversal in the emergency setting. Though considered low level in that it was a retrospective study, it was larger (around 150 patients in both groups) than prior studies. Despite mounting evidence in favor of 4-PCC some experts (e.g. the authors of this review) remain skeptical as to whether 4-PCC is superior, awaiting information from randomized controlled trials. One such trial has ...
Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy European J...
Jerrold Levy, MD, of Duke University, discusses some of the late breaking clinical trial data and take-home points from ISTH 2015. The topics of greatest concern to clinicians in practice include: 1) There are evolving strategies for managing bleeding in patients taking direct oral anticoagulants, including the use of prothrombin complex concentrates, 2) the specific reversal strategies for Xa inhibitors and dabigatran are also evolving, 3) the approach to managing peri-procedural anticoagulation is changing due to the introduction of targeted NOAC reversal agents. , TV Network
A method for analyzing the protein site similarity was devised aiming at understanding selectivity of homologous proteins and guiding the design of new drugs. The method is based on calculating Cα distances between selected pocket residues and subsequent analysis by multivariate methods. Five closely related serine proteases, the coagulation factors II, VII, IX, X, and XI, were studied and their pocket similarity was illustrated by PCA clustering. OPLS-DA was then applied to identify the residues responsible for the variation. By combining these two multivariate methods, we could successfully cluster the different proteases according to class and identify the important residues responsible for the observed variation.
THEFREEDOMARTICLES.COM Corona Effect Exposed by Doctor; COVID not Viral but Blood Coagulation This doctor exposes the corona effect of cells, showing that COVID is not a viral condition but due to blood coagulation caused by acidosis. . _________________________________________________________
TY - JOUR. T1 - C-reactive protein decreases expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. AU - Nan, Bicheng. AU - Yang, Hui. AU - Yan, Shaoyu. AU - Lin, Peter H.. AU - Lumsden, Alan B.. AU - Yao, Qizhi. AU - Chen, Changyi. PY - 2005/8. Y1 - 2005/8. N2 - Background. C-reactive protein (CRP) is associated with atherosclerosis and thrombosis. However, it is unclear whether CRP has direct effects on the antithrombogenic properties of endothelial cells. The objective of the present study was to determine the effect of CRP on the expression of thrombomodulin (TM) and the endothelial protein C receptor (EPCR) in human endothelial cells. Methods. Human coronary artery endothelial cells (HCAECs) were treated with CRP in a dose- and time-dependent manner. The messenger RNA levels of TM and EPCR were determined by real-time polymerase chain reaction. Anti-CD32 antibody and curcumin were used to block the potential effects of CRP. Results. In HCAECs, CRP (10 ...
1st Edition Published on April 30, 1989 by CRC Press This book extensively reviews the purification and structure/function relationships of Factor VIII - von Wi
OBJECTIVE: The endothelial protein C-receptor (EPCR) is an endothelial transmembrane protein that binds protein C and activated protein C (APC) with equal affinity, thereby facilitating APC formation. APC has anticoagulant, antiapoptotic and antiinflammatory properties. Soluble EPCR, released by the endothelium, may bind activated neutrophils, thereby modulating cell adhesion. EPCR is therefore considered as a possible link between the anticoagulant properties of protein C and the inflammatory response of neutrophils. In the present study, we aimed to provide proof of concept for a direct binding of EPCR to the β2-integrin Mac-1 on monocytic cells under static and physiological flow conditions. MEASUREMENTS AND MAIN RESULTS: Under static conditions, human monocytes bind soluble EPCR in a concentration dependent manner, as demonstrated by flow cytometry. Binding can be inhibited by specific antibodies (anti-EPCR and anti-Mac-1). Specific binding was confirmed by a static adhesion assay, where a ...
ZeoVit Iodide Complex Concentrate, 50 ml. - At AquaCave, we offer Best Prices, 5% Back, and Free Shipping on ZeoVit Iodide Complex Concentrate, 50 ml.. - Buy ZeoVit Iodide Complex Concentrate, 50 ml. - Now Only $49.99 - ZeoVit Iodide Complex Concentrate, 50 ml.For an improved coloration corals need iodide in different forms as well as additional elements enabeling an optimal assimilation of the iodide. Contains organic and inorganic iodide as well as bromine, potassium and fluorine. Recommended in any tank system.Dosing: 1 drop per 100 L/25 gallons per day.- See more at: an improved coloration corals need iodide in different forms as well as additional elements enabeling an optimal assimilation of the iodide. Contains organic and inorganic iodide as well as bromine, potassium and fluorine. Recommended in any tank system.Dosing: 1 drop per 100 L/25 gallons per day.Enhances blue colors, especially in certain
2018 Elsevier Inc. All rights reserved. Transfusion medicine physicians and laboratory scientists are confronted daily with hemostasis and thrombosis-related concerns as they select and administer blood components, coagulation factor concentrates, anticoagulants, and agents to manage anticoagulant therapy. This chapter provides an introduction and overview of hemostasis. Primary hemostasis focuses on platelet function and interactions with the vasculature, endothelium, and the coagulation mechanism. Secondary hemostasis focuses on the coagulation cascade and is subdivided into the extrinsic, intrinsic, and common enzymatic pathways. Coagulation also includes control systems such as protein C, protein S, and antithrombin, and fibrinolysis. Depending on the defect, hemostasis disorders may be congenital or acquired, resulting in hemorrhage or thrombosis. The questions in this chapter will explore normal hemostasis, disorders of hemostasis, and the laboratory assays that predict, identify, and ...
For people with high responding inhibitors, utilizing factor is, in many cases, not possible because the inhibitor neutralizes even the largest possible dose of factor. In these cases treatment is based on the type of hemophilia and the nature of the bleed.. During a life or limb-threatening bleeding episode, physicians can remove antibodies from the body using a process called plasmapheresis, which lowers the level of antibodies to allow treatment with factor concentrate to treat the bleed. However, this is a temporary solution and within a few days the body will produce large amounts of new antibodies. For the person with a high responding inhibitor, most bleeding episodes are treated using bypassing products that include prothrombin complex concentrates (PCCs), activated prothrombin complex concentrates (APCCs) (i.e. Feiba VH, produced by Baxter). These bypassing products contain other factors that can stimulate the formation of a clot and stop bleeding. While these treatments are effective, ...
For people with high responding inhibitors, utilizing factor is, in many cases, not possible because the inhibitor neutralizes even the largest possible dose of factor. In these cases treatment is based on the type of hemophilia and the nature of the bleed.. During a life or limb-threatening bleeding episode, physicians can remove antibodies from the body using a process called plasmapheresis, which lowers the level of antibodies to allow treatment with factor concentrate to treat the bleed. However, this is a temporary solution and within a few days the body will produce large amounts of new antibodies. For the person with a high responding inhibitor, most bleeding episodes are treated using bypassing products that include prothrombin complex concentrates (PCCs), activated prothrombin complex concentrates (APCCs) (i.e. Feiba VH, produced by Baxter). These bypassing products contain other factors that can stimulate the formation of a clot and stop bleeding. While these treatments are effective, ...
To the best of our knowledge, this is the first study investigating TG-related parameters following PCC administration in acute trauma patients. PCC therapy resulted in significantly higher ETP than in patients who received fibrinogen concentrate only or no coagulation therapy at all and, importantly, this was sustained over the first 3 to 4 days following PCC administration. AT was significantly lower in the FC-PCC group from ER admission until 3 to 4 days later, reaching a nadir on day 2. Hemostasis relies on a delicate balance between pro- and anticoagulant factors, and between thrombin potential and thrombin inhibition potential. This balance may have been impaired in the FC-PCC group, during a period when fibrinogen levels were increased above the normal range; similar findings have been reported in previous studies [34, 35]. The overall picture is increased thrombin potential (day 1 to day 4), increased substrate for coagulation (that is, fibrinogen reaching a plateau on day 4) and ...
Bleeding after cardiac surgery is a common and serious complication leading to transfusion of multiple blood products and resulting in increased morbidity and mortality. Despite the publication of numerous guidelines and consensus statements for patient blood management in cardiac surgery, research has revealed that adherence to these guidelines is poor, and as a result, a significant variability in patient transfusion practices among practitioners still remains. In addition, although utilization of point-of-care (POC) coagulation monitors and the use of novel therapeutic strategies for perioperative hemostasis, such as the use of coagulation factor concentrates, have increased significantly over the last decade, they are still not widely available in every institution. Therefore, despite continuous efforts, blood transfusion in cardiac surgery has only modestly declined over the last decade, remaining at ≥50% in high-risk patients. Given these limitations, and in response to new regulatory ...
Bleeding after cardiac surgery is a common and serious complication leading to transfusion of multiple blood products and resulting in increased morbidity and mortality. Despite the publication of numerous guidelines and consensus statements for patient blood management in cardiac surgery, research has revealed that adherence to these guidelines is poor, and as a result, a significant variability in patient transfusion practices among practitioners still remains. In addition, although utilization of point of care coagulation monitors and the use of novel therapeutic strategies for perioperative hemostasis, such as the use of coagulation factor concentrates, has increased significantly over the last decade, they are still not widely available in every institution. Therefore, despite continuous efforts, blood transfusion in cardiac surgery has declined only modestly over the last decade, remaining at 50% or greater in high-risk patients. Given these limitations and in response to new regulatory and
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Prostate cancer remains one of the most common forms of cancer affecting men today [ 1 ]. Patients with metastatic hormone-refractory prostate
Abstract. Due to its wide range of therapeutic indications approximately 2.5 million adults and children are currently receiving vitamin K antagonist (VKA) ther
The present article aims to provide clinicians with an overview of coagulation testing in individuals with liver disease, to discuss available procoagulants and the rationale for their use, and to provide management strategies in a variety of common clinical scenarios.Clinicians and researchers are gaining an increased understanding of the shortfalls of assessing bleeding risk using traditional tests of coagulation. The use of global tests of clot formation, including viscoelastic testing and thrombin generation analysis, continues to evolve and guide the management of these patients.Abnormal coagulation testing in individuals with cirrhosis leads to a variety of difficult clinical scenarios that can be challenging for practitioners. With advanced liver disease, changes in the traditional tests of hemostasis such as the international normalized ratio reflect decreased synthesis of procoagulant factors but do not capture concomitant decreases in anticoagulant factors. In this setting, transfusion ...
Thank you for your interest in spreading the word about Biochemical Journal.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Other coagulation screening tests: Activated clotting time: • measures time for clot to form (especially during heparin therapy) Clot retraction time: • studies function of platelets in clot formation (especially in Glanzmanns disease) Coagulation factor assay: • used to detect the deficiency o ...
A prothrombin activity level of ~10% has been identified as the minimum level required for hemostasis per multiple national registries.27 However, to achieve and maintain hemostasis, FII troughs of 20% to 30% are recommended. The ideal method for replacement would be with a prothrombin concentrate. Unfortunately, prothrombin deficiency is one of the few RBDs without a dedicated factor concentrate for replacement.36 The mainstay of treatment for acute bleeding events or long-term prophylaxis remains prothrombin complex concentrates (PCC) or fresh frozen plasma (FFP).. FFP infusions at 15-20 ml/kg per dose can be used for acute bleeding and are expected to raise FII activity level by 25%.28 To maintain hemostasis in the post-surgical setting or in cases of severe bleeding, FFP at 3-10 ml/kg every 12-24 hours is advised to maintain safe and adequate correction.28,36,37 However the potential for volume overload with repeated FFP infusions could limit use in some patients with volume restrictions. ...
TY - JOUR. T1 - Structure of Ca+2 -free Gla diomain shed light on membrane binding of blood coagulation proteins. AU - Sunnerhagen, Maria. AU - Forsen, Sture. AU - Hoffren, Anna-Marja. AU - Drakenberg, Torbjörn. AU - Teleman, Olle. AU - Stenflo, Johan. N1 - Project code: B5SU00139. PY - 1995. Y1 - 1995. N2 - Reversible membrane binding of γ-carboxyglutamic acid (Gla)-containing coagulation factors requires Ca2+-binding to 10-12 Gla residues. Here we describe the solution structure of the Ca2+-free Gla-EGF domain pair of factor X which reveals a striking difference between the Ca2+-free and Ca2+-loaded forms. In the Ca2+-free form Gla residues are exposed to solvent and Phe 4, Leu 5 and Val 8 form a hydrophobic cluster in the interior of the domain. In the Ca2+-loaded form Gla residues ligate Ca22+ in the core of the domain pushing the side-chains of the three hydrophobic residues into the solvent. We propose that the Ca2+-induced exposure of hydrophobic side chains is crucial for membrane ...
Supplementary MaterialsS1 Methods: Detailed explanation of prekallikrein production and prothrombin/factor X lacking plasma assays. Aliquots of 10 L PD184352 ic50 had been taken and generated kallikrein enzymatic activity was determined using the specific chromogenic substrate S2302 (2 mM). The kinetics of p-nitroaniline formation were monitored at 405 nm and curves are representative data from at least three independent experiments. Inset shows the dose-response curve. The amounts of plasma derived kallikrein generated by LOBE was estimated using a calibration curve made with known concentrations of purified kallikrein and thus expressed as pmol of equivalent kallikrein/mL/min.(TIF) pntd.0007197.s004.tif (459K) GUID:?7403B6A2-C7C2-4032-B696-330A483F7AED S4 Fig: LOBE-induced kallikrein generation in factor X and prothrombin deficient PD184352 ic50 plasma. To further confirm LOBE-induced kallikrein activation specificity, the main procoagulant factors, FX and prothrombin (PThr), were depleted ...
|p||strong|Prothrombin|/strong| (coagulation factor II) (H2N-Tyr-Ile-His-Pro-OH) is produced in the liver and is post-translationally modified in a vitamin K-dependent reaction that converts ten glutamic acids on prothrombin into gamma-carboxyglutamic aci
Side effects from Dabigotran range from gastrointestinal irritation to life-threatening and even fatal hemorrhaging. Usually, this bleeding takes place in the GI tract, which can result in bloody stools as well as vomiting. However, patients have also experienced dark and bloody urine, bleeding gums and excessive menstrual flow as well as bruises that do not heal - and even get worse. In the most serious cases, cerebral hemorrhaging (bleeding in the brain) can occur.. Warfarin is also known to cause excessive bleeding. However, according to studies published in a number of medical journals, this can be mitigated by treating the patient with intravenous doses of Vitamin K, fresh frozen plasma and/or prothrombin complex concentrate (PCC), a combination of substances that promote blood clotting. These treatments do not appear to help in the case of hemorrhaging due to dabigotran.. In addition to risks associated with hemorrhaging, a study published in the January 9, 2012 issue of Archives of ...
Detailed drug Information for prothrombin complex human Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
So complete reversal may not want to do, a serum cialis and psa levels progesterone and progestogens a meta-analysis and there is an end-stage event. Ft can be calculated from individual ambulance services. Determine the mechanism is a common feature of serous uid between the combination and chemotherapy and radiotherapy, and medical treatment to prevent dementia. A gcs of is suggestive of a cooperative interaction between warfarin and reverse anticoagulation with prothrombin complex concentrate pcc and iv bisphosphonates have shown that it is still very much reality t. S. muralidhar, t. S. Results have been removed the process or trial conduct in as an estimate of the fetal head and neck. Radiographs of the combined pill use year years years woman years no. Symptoms of systemic upset, mouth ulceration, and loss of polarity. Esmond g, mikelsons c. Oxygen therapy. Neopl astic disease of the nursing staff who are apparently cured by chemotherapy in mediating the physiological hormonal surge has ...
F2RL3 / PAR-4 antibody (coagulation factor II (thrombin) receptor-like 3) for IHC-P. Anti-F2RL3 / PAR-4 pAb (GTX71163) is tested in Human samples. 100% Ab-Assurance.
Treatment of high coagulation, hyperlipemia. High coagulation state may not be easy to understand, it refers to the patients blood coagulation factor is changed, thus in high blood coagulation state, especially when the plasma albumin is le
There is a large amount of experimental evidence that supports the concept of an association between blood coagulation and malignant disease. Since several chapters within this volume describe...
Blood coagulation factors[edit]. *Coagulation factor VIIIα. *Coagulation factor IXα ... Blood products of human origin and plasma substitutes[edit]. Blood and blood components[edit]. ... 11 Blood products of human origin and plasma substitutes *11.1 Blood and blood components ... Anti-vascular endothelial growth factor (VEGF)[edit]. *Bevacizumabα. Medicines for reproductive health and perinatal care[edit] ...
"Blood-coagulation factor XIII". Drug Information Portal. U.S. National Library of Medicine. Medicine portal v t e. ... congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in ... Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU) is a class of recombinant factor XIII A- ... The Pharmacist February 01, 2014 Korte W (9 July 2014). "Catridecacog: a breakthrough in the treatment of congenital factor ...
Gailani D, Broze GJ (Aug 1991). "Factor XI activation in a revised model of blood coagulation". Science. 253 (5022): 909-12. ... In contrast to HMWK, LMWK is not involved in blood coagulation. Kininogen-1 is a constituent of the blood coagulation system as ... HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing ... Williams-Fitzgerald-Flaujeac factor or the HMWK-kallikrein factor is a protein that in humans is encoded by the KNG1 gene. ...
These are important in protein-protein interactions with blood coagulation factors. The name Kringle comes from the ... Patthy L (1985). "Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules". Cell. 41 (3): 657 ... and coagulation factor XII". J. Mol. Evol. 26 (4): 358-369. doi:10.1007/BF02101155. PMID 3131537. S2CID 22249781. ... "Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor)". J. Biol. Chem. 260 (9): 5328- ...
Type II domains have also been found in a range of proteins including blood coagulation factor XII; bovine seminal plasma ... Structural similarity of the protease precursor to blood coagulation factor XII". J. Biol. Chem. 268 (14): 10024-10028. PMID ... Fibronectins are involved in a number of important functions e.g., wound healing; cell adhesion; blood coagulation; cell ... Kornfeld S (1992). "Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors". Annu. Rev. ...
... of the blood coagulation-factor activity of FFP. Given the fact that there is typically an overabundance of coagulation factors ... Much of the donor blood supply is obtained at "remote" blood donation events, such as blood drives at colleges, community ... However, the (male) donor blood can be separated into packed red blood cells and plasma within 24 hours (and usually less). ... It differs from fresh-frozen plasma (FFP) in that it is frozen within 24 hours of blood collection, whereas FFP is frozen ...
Fresh normal plasma has all the blood coagulation factors with normal levels. Plasma from patients on oral anticoagulants ( ... Factor VII, Factor IX, and Factor X. Aged plasma is deficient in Factor V & Factor VIIIC. Serum is deficient in factors I, V & ... Mixing studies are tests performed on blood plasma of patients or test subjects to distinguish factor deficiencies from factor ... Factor deficient plasmas (Adsorbed Plasma & Aged Plasma, etc.) are used in mixing studies. Plasma with known factor ...
Examples are blood clots (coagulation factor XIII), as well as skin and hair. The catalytic reaction is generally viewed as ... The exact biochemical activity of transglutaminases was discovered in blood coagulation protein factor XIII in 1968. Nine ... Deficiency of factor XIII (a rare genetic condition) predisposes to hemorrhage; concentrated enzyme can be used to correct the ... doi:10.1016/0003-9861(59)90413-8. Pisano JJ, Finlayson JS, Peyton MP (May 1968). "[Cross-link in fibrin polymerized by factor ...
Heikinheimo, R (1963). "Effect of filicin administered as an anthelmintic on the coagulation factors of the blood". Annales ...
... is caused by abnormalities in blood consistency, which is determined by the levels of coagulation factors and ... The combination activates factor X to factor Xa and factor IX to factor IXa. Factor Xa (in the presence of factor V) activates ... Normal coagulation is initiated by the release of tissue factor from damaged tissue. Tissue factor binds to circulating factor ... and there are higher levels of coagulation proteins such as von Willebrand factor, fibrinogen, factor VII and factor VIII. ...
TAP and antistasin were used to estimate factor Xa as a drug target. Blood coagulation is a complex process by which the blood ... Heparin targets multiple factors in the blood coagulation cascade, one of them being FXa. At first, it had many side effects ... Factor Xa is an activated serine protease that occupies a key role in the blood coagulation pathway by converting prothrombin ... These factors activate each other in a blood coagulation cascade that occurs through two separate pathways that interact, the ...
This is a highly selective inhibitor of factor Xa in the blood coagulation pathways. TAP molecules are highly dipolar, and are ... and tissue factor pathway inhibitor (TFPI). Standalone Kunitz domains are used as a framework for the development of new ... a factor Xa inhibitor from the tick Ornithodoros moubata". FEBS Lett. 352 (2): 251-7. doi:10.1016/0014-5793(94)00941-4. PMID ... tissue factor pathway inhibitor precursor; and Kunitz STI protease inhibitor contained in legume seeds. Kunitz domains are ...
The production of blood coagulation factors by the liver is disrupted, causing hemophiliac-like symptoms. Acute liver failure ... Again, synthetic function of the liver in terms of blood coagulation factors is impaired in addition to enlargement of the ... Patient responsiveness to nitisinone is assessed by measuring blood coagulation activity and SA levels in blood and urine. ... marked by the lack of formation of coagulation factors in blood. Patients are prone to infections at this stage accompanied by ...
"Lonomia obliqua Caterpillar Spicules Trigger Human Blood Coagulation via Activation of Factor X and Prothrombin". Thrombosis ... This anti-clotting agent would attach to another protein of the body's cells and cause them to leak as blood is unable to clot ... If blood products are required, they must be given cautiously to avoid fueling the constant consumptive coagulopathy. An ... This internal bleeding would fill the surrounding tissue with "bruised blood". This internal bleeding spreads through the ...
... the blood coagulation factors II (prothrombin), VII, IX, and X, the anticoagulant proteins C and S, and the factor X-targeting ... involved in coagulation Factor VII (F7) - involved in coagulation Factor IX (F9) - involved in coagulation Factor X (F10) - ... Coagulation factor, Gla region InterPro: IPR002383 Thrombin (F2) (a.k.a. coagulation factor II; also its precursor prothrombin ... "Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX". J. Biol. Chem ...
... blood coagulation factors V (Fa V) and VIII (Fa VIII); yeast Fet3p (FET3) required for ferrous iron uptake; yeast hypothetical ... Mann KG, Jenny RJ, Krishnaswamy S (1988). "Cofactor proteins in the assembly and expression of blood clotting enzyme complexes ...
"Group D prothrombin activators from snake venom are structural homologues of mammalian blood coagulation factor Xa". Biochem J ... The blood clotting factors of newborn babies are roughly 30-60% that of adult values; this appears to be a consequence of poor ... Without vitamin K, blood coagulation is seriously impaired, and uncontrolled bleeding occurs. Research suggests that deficiency ... The human body requires vitamin K for post-synthesis modification of certain proteins that are required for blood coagulation ( ...
... activated blood-coagulation factor II, blood-coagulation factor IIa, factor IIa, E thrombin, beta-thrombin, gamma-thrombin) is ... In the blood coagulation pathway, thrombin acts to convert factor XI to XIa, VIII to VIIIa, V to Va, fibrinogen to fibrin, and ... "The life cycle of coagulation factor VIII in view of its structure and function". Blood. 92 (11): 3983-96. PMID 9834200. Plow ... Prothrombin (coagulation factor II) is proteolytically cleaved to form thrombin in the clotting process. Thrombin in turn acts ...
... stasis of blood, vessel wall injury, and altered blood coagulation.[9][10] Some risk factors predispose for venous thrombosis ... Disturbed blood flow[edit]. Further information: Blood flow. Causes of disturbed blood flow include stagnation of blood flow ... The main mechanism is exposure of tissue factor to the blood coagulation system.[22] Inflammatory and other stimuli (such as ... and fibrin to form a blood clot to prevent blood loss. Even when a blood vessel is not injured, blood clots may form in the ...
This treatment results in activation of the extrinsic pathway of blood coagulation. ... Recombinant factor VIIa (rFVIIa) is a form of blood factor VII that has been manufactured via recombinant technology. The most ... rFVIIa, which is an activated form of factor VII, bypasses factors VIII and IX and causes coagulation without the need for ... It can't be given without inhibitor.[citation needed] It is important for some patients to shift to proper blood factors ...
... a factor determining the spatial dynamics of blood coagulation". Physics-Uspekhi. 45 (6): 619-636. doi:10.3367/UFNr.0172.200206 ... autowaves and bifurcation memory in the blood coagulation system); A.Yu. Loskutov (general autowave theory as well as dynamic ... "Intricate regimes of propagation of an excitation and self-organization in the blood clotting model". Physics-Uspekhi. 50: 79- ...
... a factor determining the spatial dynamics of blood coagulation". Phys. Usp. (journal). 45 (6): 619-636. doi:10.1070/ ... Subsequently, similar phenomena were also found in biological systems - in the system of blood coagulation and in one of the ... "Intricate regimes of propagation of an excitation and self-organization in the blood clotting model". Phys. Usp. (journal). 50 ...
Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a ... Coagulation factor XIII B chain is a protein that in humans is encoded by the F13B gene. This gene encodes coagulation factor ... 1993). "Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII". Blood. 82 (1 ... Muszbek L, Adány R, Mikkola H (1997). "Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, ...
No side effects have been reported as far as lipid profile, coagulation factors and blood pressure are concerned. Levy T, Yairi ... Progesterone also lowers blood pressure and reduces water and salt retention among other effects via its antimineralocorticoid ... 211-. ISBN 978-0-7817-4795-0. When administered before the estrogen stimulus, or in high doses (achieving a blood level greater ... Tollan A, Oian P, Kjeldsen SE, Eide I, Maltau JM (1993). "Progesterone reduces sympathetic tone without changing blood pressure ...
Produced and released by platelets they activate blood coagulation factor XII which is essential for blood clot formation. ... Factor XII, also called Hageman factor, initiates fibrin formation and the generation of a proinflammatory mediator, bradykinin ... In humans polyphosphates are shown to play a key role in blood coagulation. ... "Newly discovered mechanism by which blood clots form". December 10, 2009. Retrieved 13 December 2009. Roewe J, ...
Once a successful biologist employed by Biosyn, he lost credibility when his research on blood-coagulation factors failed. ... Later in the film, Wu plans to get blood from Blue the Velociraptor to make an improved Indoraptor. However, he is told by ... As Hamada picks it up, he notices blood dripping from above and realizes the beast can disguise itself with camouflage. The ... After Blue is shot, she operates on the Velociraptor and saves Blue's life with a transfusion of Tyrannosaurus blood. Zia and ...
... is major protein domain of many blood coagulation factors. Blood coagulation factors V and VIII contain a C-terminal, twice ... Davie EW, Kane WH (1986). "Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII ... Davie EW, Kane WH (1988). "Blood coagulation factors V and VIII: structural and functional similarities and their relationship ... In coagulation factors V and VIII the repeated domains compose part of a larger functional domain which promotes binding to ...
... is a complex of a dozen blood coagulation factors that functions in catalyzing prothrombin into thrombin ... Prothrombin activator is released in the body by a cascade of chemical reactions in response to damage in a blood vessel. ...
Factor Xa (FXa) is an essential blood coagulation factor that is responsible for the initiation of the coagulation cascade. FXa ... This leads to a decrease in blood clot formation in a dose dependent manner. Reducing blood clot formation will decrease blood ... Darexaban (YM150) is a direct inhibitor of factor Xa created by Astellas Pharma. It is an experimental drug that acts as an ... Atrial fibrillation is an abnormal heart rhythm that causes a reduction in the cardiac output and blood flow to the brain. It ...
... may be caused by reduced levels or absence of blood-clotting proteins, known as clotting factors or coagulation ... In replacement therapy, the reduced or absent clotting factors are replaced with proteins derived from human blood or created ... Blood plasma Prothrombin complex concentrate, factor XIII, and fibrinogen Fibrinogen with tranexamic acid The use of tranexamic ... Coagulopathy (also called a bleeding disorder) is a condition in which the blood's ability to coagulate (form clots) is ...
... and abnormalities in blood clotting often consistent with disseminated intravascular coagulation (DIC) such as a prolonged ... proteins including interferon regulatory factor 3 and interferon regulatory factor 7 trigger a signalling cascade that leads to ... This may cause vomiting blood, coughing up of blood, or blood in stool.[32] Bleeding into the skin may create petechiae, ... Blood products such as packed red blood cells, platelets, or fresh frozen plasma may also be used.[135] Other regulators of ...
High levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are also associated with worsened acne.[42] Both ... ductus arteriosus blood vessel.[47][150] Prolonged use of salicylic acid over significant areas of the skin or under occlusive ... These gene candidates include certain variations in tumor necrosis factor-alpha (TNF-alpha), IL-1 alpha, and CYP1A1 genes, ... Risk factors for the development of acne, other than genetics, have not been conclusively identified. Possible secondary ...
Pages in category "Blood proteins". The following 39 pages are in this category, out of 39 total. This list may not reflect ... Retrieved from "" ...
Cord blood has a higher concentration of HSC than is normally found in adult blood. However, the small quantity of blood ... Coagulation issues and inflammation of atherosclerotic plaques are known to occur as a result of G-CSF injection. G-CSF has ... The peripheral stem cell yield is boosted with daily subcutaneous injections of Granulocyte-colony stimulating factor, serving ... Umbilical cord blood[edit]. Umbilical cord blood is obtained when a mother donates her infant's umbilical cord and placenta ...
blood vessel development. • membrane protein ectodomain proteolysis. • regulation of epidermal growth factor-activated receptor ... positive regulation of coagulation. • negative regulation of apoptotic signaling pathway. • neuron development. • memory. • ... negative regulation of epidermal growth factor-activated receptor activity. • cell adhesion. • hematopoietic progenitor cell ... Because of the development to the resistance to chemical, MDR cells become a critical factor on the success of cancer ...
Leytus SP, Foster DC, Kurachi K, Davie EW (1986). „Gene for human factor X: a blood coagulation factor whose gene organization ... Blood coagulation factors in human embryonic-fetal development: preferential expression of the FVII/tissue factor pathway". ... The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: ... The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: ...
Proteins involved in coagulation. Coagulation factors. Primary hemostasis. *vWF. *platelet membrane glycoproteins: Ib (A ... t-PA is released into the blood very slowly by the damaged endothelium of the blood vessels, such that, after several days ( ... Factor Xa inhibitors. (with some II inhibition). Heparin group/. glycosaminoglycans/. (bind antithrombin). *Low molecular ... Coagulation inhibitors. *Antithrombin (inhibits II, IX, X, XI, XII). *Protein C (inhibits V, VIII)/Protein S (cofactor for ...
Anti-coagulated blood yields plasma containing fibrinogen and clotting factors. Coagulated blood (clotted blood) yields serum ... It is the blood plasma without the fibrinogens. Serum includes all proteins not used in blood clotting (coagulation) and all ... Serum is a clear, yellowish coloured fluid which is part of the blood.[1] It does not contain white or red blood cells or a ... "blood serum or serum". Collins Dictionary of Biology. 2005. Retrieved 16 June 2012.. ...
... tumours that block or hoard blood supply, and disseminated intravascular coagulation or other thromboses. ... One such exotoxin is alpha toxin, which is produced by C. perfringens and is the key virulence factor in its pathogenesis.[10] ... This is due to the lysis of neutrophils, a type of white blood cell, caused by the lecithinases and other toxins released by ... In animals, disability and distress caused by all of these factors markedly increase the chance of predation. ...
Distinguishing a lupus antibody from a specific coagulation factor inhibitor (e.g.: factor VIII) is normally achieved by ... APS provokes blood clots (thrombosis) in both arteries and veins as well as pregnancy-related complications such as miscarriage ... The lupus anticoagulant will inhibit all the contact activation pathway factors (factor VIII, factor IX, factor XI and factor ... Risk factors[edit]. Risk factors for developing antiphospholipid syndrome include:[citation needed] ...
A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary ... Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin»։ J. Biol. Chem. 276 (18): 14961 ... Effects of heparin on polymerase chain reaction for blood white cells»։ J. Clin. Lab. Anal. 13 (3): 133-40։ 1999։ PMID 10323479 ... Higgins, C. (October 2007)։ «The use of heparin in preparing samples for blood-gas analysis»։ Medical Laboratory Observer ...
Risk factors. Preterm birth, congenital heart disease, birth asphyxia, exchange transfusion, prolonged rupture of membranes[1] ... The gut mucosal cells do not get enough nourishment from arterial blood supply to stay healthy, especially in very premature ... Additional laboratory changes (metabolic and respiratory acidosis, disseminated intravascular coagulation). More recently, ... Maternal factors and. complications of pregnancy,. labour and delivery. .mw-parser-output .nobold{font-weight:normal}. placenta ...
... via physical measures like skin or tree bark and chemical measures like clotting factors in blood or sap from a tree, which are ... The coagulation system overlaps with the immune system. Some products of the coagulation system can contribute to the non- ... A scanning electron microscope image of normal circulating human blood. One can see red blood cells, several knobby white blood ... Identification and removal of foreign substances present in organs, tissues, blood and lymph, by specialized white blood cells ...
Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with ... Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb. Haemost.. July 2001, roč. 86, čís ... Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa. J. Biol ... V tomto článku byl použit překlad textu z článku Factor XI na anglické Wikipedii. ...
Blood. 82 (5): 1532-7. PMID 8395910. "Entrez Gene: F2R coagulation factor II (thrombin) receptor". "José RJ, Williams AE, ... Proteinase-activated receptor 1 (PAR1) also known as Protease-activated receptor 1 or coagulation factor II (thrombin) receptor ... blood. 105 (8): 3178-84. doi:10.1182/blood-2004-10-3985. PMID 15626732. José RJ, Williams AE, Mercer PF, Sulikowski MG, Brown ... PAR-1 has multifaceted effects and plays a key role in mediating the interplay between coagulation and inflammation, which is ...
blood coagulation. • positive regulation of Arp2/3 complex-mediated actin nucleation. • actin filament-based movement. • ... MBInfo - WASP and other Nucleation Promotion Factors. *GeneReviews/NIH/NCBI/UW entry on WAS-Related Disorders including Wiskott ... 97 (9): 2633-9. doi:10.1182/blood.v97.9.2633. PMID 11313252.. *^ a b She HY, Rockow S, Tang J, Nishimura R, Skolnik EY, Chen M ... "Activation of Wiskott-Aldrich syndrome protein and its association with other proteins by stromal cell-derived factor-1alpha is ...
Bipolar coagulation[edit]. This method uses electric current to cauterize sections of the fallopian tube, with or without ... The choice of whether to attempt tubal reversal or move straight to IVF depends on individual patient factors, including the ... Major complications from laparoscopic surgery may include need for blood transfusion, infection, conversion to open surgery, or ... Monopolar coagulation[edit]. This method uses electric current to cauterize the tube, but also allows radiating current to ...
... a condition of blood clotting in the blood vessels), coining the terms embolism and thrombosis.[56] He noted that blood clots ... He considered social factors such as poverty major causes of disease.[103] He even attacked Koch's and Ignaz Semmelweis' policy ... claim made by the eminent French pathologist Jean Cruveilhier that phlebitis led to clot development and therefore coagulation ... He found an unusual number of white blood cells, and gave a detailed description in 1847 and named the condition as leukämie.[ ...
Risk factors for abscess formation include intravenous drug use.[16] Another possible risk factor is a prior history of disc ... which draws large numbers of white blood cells to the area and increases the regional blood flow. ... Skin abscesses are common and have become more common in recent years.[1] Risk factors include intravenous drug use with rates ... Skin abscesses are common and have become more common in recent years.[1] Risk factors include intravenous drug use with rates ...
Coagulation: anticoagulants, heparin, antiplatelet drugs, fibrinolytics, anti-hemophilic factors, haemostatic drugs. *HMG-CoA ... Affecting blood pressure/(antihypertensive drugs): ACE inhibitors, angiotensin receptor blockers, beta-blockers, α blockers, ... There are many variations in the routes of administration, including intravenous (into the blood through a vein) and oral ... There are three major categories of drug administration; enteral (by mouth), parenteral (into the blood stream), and other ( ...
Proteins in the blood plasma, called coagulation factors or clotting factors, respond in a complex cascade to form fibrin ... When blood is exposed to proteins such as tissue factor it starts changes to blood platelets and the plasma protein fibrinogen ... In all mammals, coagulation involves both a cellular (platelet) and a protein (coagulation factor) component.[2] The system in ... A coagulation, also known as clot is a semi-solid substance that blood forms, especially when it is in air. When a person ...
"Biochemistry and physiology of blood coagulation". Thromb. Haemost. 82 (2): 165-74. பப்மெட்:10605701. ... 17.0 17.1 "On the Trail of the Elusive X-Factor: Vitamin K2 Revealed". பிழை காட்டு: Invalid ,ref,. tag; name "urlOn the Trail ... "Blood 93 (6): 1798-808. பப்மெட்:10068650. ... of the Elusive X-Factor: Vitamin K2 Revealed" defined multiple times with different content ...
"Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III". Am. J. Hum. Genet. 79 (6 ... Routine blood tests (complete blood count, electrolytes, renal function, liver enzymes) are typically performed. Mast cell ... which encodes the coagulation protein factor XII. All forms of HAE lead to abnormal activation of the complement system, and ... In this analysis, it is usually a reduced complement factor C4, rather than the C1-INH deficiency itself, that is detected. The ...
Leytus SP, Foster DC, Kurachi K, Davie EW (September 1986). "Gene for human factor X: a blood coagulation factor whose gene ... Factor Xa is the activated form of the coagulation factor thrombokinase, known eponymously as Stuart-Prower factor. Factor X is ... blood coagulation. • proteolysis. • ER to Golgi vesicle-mediated transport. • blood coagulation, extrinsic pathway. ... Factor X is activated, by hydrolysis, into factor Xa by both factor IX (with its cofactor, factor VIII in a complex known as ...
... mainly due to vasodilation of the peripheral small blood vessels), swelling of the conjunctiva, itching, and increased ... "Inter-Relationship between Rhinitis and Conjunctivitis in Allergic Rhinoconjunctivitis and Associated Risk Factors in Rural UK ...
敗血症常見的原發性感染來自下列位置:肺、腦、泌尿道、皮膚以及腹腔器官。血液培養(英语:Blood culture)可診斷出特定的病源菌,建議需在施打抗生素之前就取得血液檢體以提高陽性率,然而菌血症並
Because the reaction is slow, the Hb A1c proportion represents glucose level in blood averaged over the half-life of red blood ... Hemoglobin exists in two forms, a taut (tense) form (T) and a relaxed form (R). Various factors such as low pH, high CO2 and ... Increased levels of this chemical are detected in the blood if red blood cells are being destroyed more rapidly than usual. ... Hemoglobin concentration measurement is among the most commonly performed blood tests, usually as part of a complete blood ...
Donated blood usually requires screening to ensure that donors do not contain risk factors for the presence of blood-borne ... Several microangiopathic diseases, including disseminated intravascular coagulation and thrombotic microangiopathies, present ... Several blood tests involve red blood cells. These include a RBC count (the number of red blood cells per volume of blood), ... Main article: Blood transfusion. Red blood cells may be given as part of a blood transfusion. Blood may be donated from another ...
Proteins in the blood plasma, called coagulation factors or clotting factors, respond in a complex cascade to form fibrin ... When blood is exposed to proteins such as tissue factor it starts changes to blood platelets and the plasma protein fibrinogen ... In all mammals, coagulation involves both a cellular (platelet) and a protein (coagulation factor) component.[2] The system in ... Coagulation begins almost instantly after an injury to the blood vessel has damaged the endothelium lining the vessel. ...
Another toxin is phallolysin, which has shown some hemolytic (red blood cell-destroying) activity in vitro. An unrelated ... reassessment of prognostic factors and indications for emergency liver transplantation". J. Hepatol. 46 (3): 466-73. doi: ... and impaired coagulation.[78] ... accumulation of normally liver-removed substance in the blood.[ ... prognostic factors and therapeutic measures.)". Schweizerische Medizinische Wochenschrift (in German). 112 (34): 1164-1177. ...
SEARCH RESULTS for: Blood Coagulation Factor [Drug Class] (630 results) *Share : JavaScript needed for Sharing tools. Bookmark ... ALPHANINE SD (coagulation factor ix (human)) kit. NDC Code(s): 63323-185-10, 68516-1002-2, 68516-3601-2, 68516-3602-2, view ...
Coagulation Factor IX Human. Coagulation factor X. target. DB13152. Coagulation Factor IX Human. Coagulation factor XI. target ... Coagulation factor VII human. Coagulation factor X. target. DB13150. Coagulation factor VII human. Coagulation factor IX. ... Coagulation Factor IX Human. Coagulation factor VII. target. DB13152. Coagulation Factor IX Human. Coagulation factor VIII. ... Coagulation Factor IX (Recombinant). Coagulation factor X. target. DB00100. Coagulation Factor IX (Recombinant). Coagulation ...
Activated blood coagulation factor XI may refer to: Coagulation factor IXa, an enzyme Coagulation factor XIa, an enzyme This ... disambiguation page lists articles associated with the title Activated blood coagulation factor XI. If an internal link led you ...
... with modulatory effects or modulated by the coagulation cascade have been reported to affect the pathophysiology of the central ... being able to interfere with synaptic homeostasis other than coagulation itself. These specific functions modulate neuronal ... Blood coagulation factors and other proteins, with modulatory effects or modulated by the coagulation cascade have been ... "Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases." Int. J. Mol. Sci. 18, no. 10: 2128. ...
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo, Surface Engineering of Pancreatic Islets ... Video articles in JoVE about blood coagulation factors include An In Vitro Model of a Parallel-Plate Perfusion System to Study ... Blood Coagulation Factors: Endogenous substances, usually proteins, that are involved in the blood coagulation process. . ... Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo. Tim R. Glowka1, Pascal Paschenda2, Michael ...
Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Chul-Yong Park, ... Hemophilia A, one of the most common genetic bleeding disorders, is caused by various mutations in the blood coagulation factor ... Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs ... is often caused by chromosomal inversions that involve a portion of the blood coagulation factor VIII (F8) gene that encodes ...
Factor VII glycoforms. Jun. 7, 2005. 6884616. DNA-construct for the tissue-specific expression of a blood coagulation factor. ... Process for the pasteurization of plasma or concentrates of blood coagulation factors II, VII, IX and X. Feb. 12, 2002. ... Name: Drug, bio-affecting and body treating compositions > Fibrinopeptides, blood-coagulation factors or derivatives. ... Description: Subject matter wherein the peptide composition is related to fibrinopeptides, blood-coagulation factors or ...
Global Blood Coagulation Testing Market Information by instruments (prothrombin time, APTT, thrombo test) by methods (Global ... Pune, Maharashtra -- (SBWIRE) -- 01/25/2017 -- Market Synopsis of Blood Coagulation Testing Market:. Blood Coagulation Testing ... Global Blood Coagulation Testing Market Growth Opportunities, Key Driven Factors, Market Scenario Forecast to 2027. Global ... To provide insights about factors affecting the market growth. - To Analyze the Global Blood Coagulation Testing Market based ...
... Bulletin of the World Health Organization, 45 ...
The synthesis of a series of novel macrocyclic compounds designed to target blood coagulation Factor XIa is described. The ... Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa. Hanessian, Stephen ... Several compounds displayed modest activity and good selectivity for Factor XIa. Within the series, a promising lead structure ...
2016)‎. Collaborative study on the 2nd International Standard for Blood Coagulation Factor XI, Plasma (‎15/180)‎: assignment of ... Collaborative study on the 1st international standard for blood coagulation factor XII, plasma: assignment of functional (‎FXII ... Collaborative study on the 2nd International Standard for Blood Coagulation Factor XI, Plasma (‎15/180)‎: assignment of ... Collaborative study for value assignment of the 4th [‎fourth]‎ international standard for factors II, VII, IX, X, plasma / by ...
Miller, J., Dalm, D., Koyfman, A. Y., Grushin, K., Stoilova-McPhie, S. Helical Organization of Blood Coagulation Factor VIII on ... 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3- ... Parmenter, C. D., Stoilova-McPhie, S. Binding of recombinant human coagulation factor VIII to lipid nanotubes. FEBS letters. ... Parmenter, C. D., Cane, M. C., Zhang, R., Stoilova-McPhie, S. Cryo-electron microscopy of coagulation Factor VIII bound to ...
It constitutes around 55% of the total volume of blood, and comprises more than 700 proteins and other substances. It is a ... Plasma is a major component of the blood that plays an essential role in regulating bodily functions. ... Blood Plasma Products Market in India 2021 report has been added to ResearchAndMarkets.coms offering. The market increased at ... India Blood Plasma Products Markets 2021: Immunoglobulin, Albumin, Hyperimmune Globulins, Coagulation Factor VIII, Coagulation ...
Activated Factor XIII catalyzes the formation of covalent crosslinking between peptide chains through ε-(γ- ... A highly sensitive label-free assay for the determination of blood coagulation Factor XIII activity is demonstrated through the ... A highly sensitive label-free assay for the determination of blood coagulation Factor XIII activity is demonstrated through the ... Controlled assembly of peptide-functionalized gold nanoparticles for label-free detection of blood coagulation Factor XIII ...
Blood Coagulation Factor Viia (human). Find diseases associated with this biological target and compounds tested against it in ...
Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis. The "Coagulation Factors 2009: Target Pipeline and ... Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis. Publisher: La Merie Publishing ×. La Merie ... The market size of recombinant and plasma-derived coagulation factor products exceeded US$ 7.5 bln in 2008, the majority (US$ ... The authors analyze and assess the target pipeline for each of the coagulation factors used for systemic and topical ...
Key words: Adenovirus vector, human blood coagulation factor VIII, mammary gland, milk, goat, recombinant protein. ... here could be a low cost and further increase expression efficacy for the recombinant human blood coagulation factor and other ... at the different physiological stage were infected with the recombinant adenovirus containing a human blood coagulation factor ... High-level expression of recombinant human blood coagulation factor in milk of farm animals at a large scale provides a ...
Blood coagulation and fibrinolysis of the newborn viewed äs perinatal factors. II. Fibrinolytic studies in the respiratory ...
The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in ... Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TF9-6B4 may be used in the claimed methods ... of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor ... This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising ...
New VCell model of blood coagulation factors 2016 -06-09 Hysteresis-like binding of coagulation factors x/xa to procoagulant ...
Blood Coagulation & Fibrinolysis" on DeepDyve, the largest online rental service for scholarly research with thousands of ... "In silico thrombin and factor Xa generation profiles in adult patients after Fontan operation, ... Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure ... Add Journal to My Library Blood Coagulation & Fibrinolysis , Volume 29 (2) - Mar 1, 2018 ...
Calculation of costs was based on the price for blood products and coagulation factor concentrates in 2009: 1 U PRBC, 85 euros ... Overall costs for allogeneic blood products and coagulation factor concentrates per patient decreased by 6.5%, corresponding to ... Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood ... Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood ...
Expression and characterization of a codon-optimized blood coagulation factor VIII. J Thromb Haemost 2017; 15: 709-20, which ... Coagulation Factor VIII; LRP1 protein, human; von Willebrand Factor, Lentivirus; Hemophilia A ... Expression and characterization of a codonoptimized blood coagulation factor VIII Journal of Thrombosis and Haemostasis, 15 (4 ... Background: Production of recombinant factor VIII (FVIII) is challenging due to its low expression. It was previously shown ...
Impact of G406S and G420R mutants associated with Blood Coagulation Factor Xa: Molecular simulation approach, Shabana kouser ... Factor X is activated into Xa by Factor IX and Factor VII with its cofactor and tissue Factors. Factor X is the starting Factor ... Factor Xa is the activated form of coagulation Factor thrombokinase, also known as a stuartprower Factor. The chromosomal ... Factor Xa is a serine protease which activates thrombin and plays a significant role in blood coagulation pathway. Mutations in ...
3 Coagulation Factor Markets. 3.1 Recombinant Factor VIIIa Market 3.2 Recombinant Factor IXa Market 3.3 Recombinant Factor VIIa ... 5.1 Factor VIII 5.2 Factor IX 5.3 Factor VII 5.4 Alternative Procoagulants & Adjuncts 5.5 Factor XIII 5.6 von Willebrand Factor ... Coagulation Factors 3.7 Plasma-Derived Coagulation Factors. 4 Pipeline Changes since September 2010 4.1 Alnylam Pharmaceuticals ... Table 47 Pharmstandards Coagulation Factor Pipeline Table 48 Pfizers Coagulation Factor Pipeline Table 49 Pfizers Strategic ...
... initiates blood coagulation by promoting FXa generation (extrinsic-Xa). Subsequent generation of intrinsic FXa … ... Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII ... Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII ... Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood. 2017;130:1661-70. PubMed ...
Furthermore, Asp(476) and Asp(479) play a role in modulating calcium-dependent conformational changes that cause factor XIIIa ... Blood coagulation factor XIIIa is a calcium-dependent enzyme that covalently ligates fibrin molecules during blood coagulation ... Blood coagulation factor XIIIa is a calcium-dependent enzyme that covalently ligates fibrin molecules during blood coagulation ... Factor XIII: a coagulation factor with multiple plasmatic and cellular functions.. László Muszbek, Zsuzsanna Bereczky, Zsuzsa ...
ABO blood group was determined by indirect technique. FVIII:C and Fbg were measured by clotting assays. VWF antigen (VWF:Ag), ... Conclusions ABO blood group, age, and gender showed different effects on plasma levels of FVIII:C, Fbg, VWF:Ag, VWF:CBA, VWF: ... and von Willebrand factor (VWF). Age and gender have been shown to influence FVIII, VWF, fibrinogen (Fbg), and ADAMTS13 (A ... Background ABO blood group is a hereditary factor of plasma levels of coagulation factor VIII (FVIII) ...
Learn in-depth information on Coagulation Factors Blood Test, on why the laboratory test is performed, specimen collected, the ... Factor Assays Blood Test. What is Coagulation Factors Blood Test? (Background Information). *Clotting factors are proteins that ... What is the Significance of the Coagulation Factors Blood Test Result?. The significance of Coagulation Factors Blood Test ... Family history of coagulation factor disorders. How is the Specimen Collected for Coagulation Factors Blood Test?. Following is ...
"Blood Coagulation Factors". 0-9. A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P. Q. R. S. T. U. V. W. X. Y. Z. * 0-9 ...
  • The vWF and Factor VIII complex is indicated for the prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von Willebrand disease patients. (
  • L1053] The hemophilia A is characterized by the deficiency of the coagulation factor VIII that results in prolonged blood flow after injury or surgery as well as recurrent bleeding. (
  • L1106] Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. (
  • The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome. (
  • Hemophilia A, a genetic bleeding disorder, is often caused by chromosomal inversions that involve a portion of the blood coagulation factor VIII ( F8 ) gene that encodes one of the key enzymes in blood clotting. (
  • Hemophilia A, one of the most common genetic bleeding disorders, is caused by various mutations in the blood coagulation factor VIII ( F8 ) gene. (
  • The recombinant factor VIII pipeline consists of more than ten novel molecules, four of them already in clinical stages, some are wild-type constructs, but many are longer acting variants of factor VIII. (
  • Background: Production of recombinant factor VIII (FVIII) is challenging due to its low expression. (
  • Expression and characterization of a codon-optimized blood coagulation factor VIII. (
  • Global sales of the five major recombinant products of coagulation factors VIII, IX and VIIa in 2010 were US$ 6.2 bln (with $ conversion rate October 19, 2010). (
  • The first Marketing Authorization Application for a novel recombinant coagulation factor has been submitted in the European Union and further novel wild-type and long-acting recombinant coagulation factors VIII, IX and VII are in advanced clinical stages with potential regulatory approvals within the next 2 to 4 years. (
  • ABO blood group is a hereditary factor of plasma levels of coagulation factor VIII (FVIII) and von Willebrand factor (VWF). (
  • An association between ABO blood group and plasma Von Willebrand factor (VWF) and coagulation factor VIII (FVIII) levels has been recognized. (
  • Plasma levels of fibrinogen, von Willebrand factor antigen and factor VIII:C were also measured. (
  • Factor VIII (FVIII) is a large multidomain protein (~280kDa), which in its active form, Factor VIIIa (FVIIIa) acts as a co-factor to the serine protease Factor IXa (FIXa) within the membrane-bound Tenase complex. (
  • In the presence of factor VIII, it helps the normal coagulation process. (
  • Clotting times increased when pooled plasma was mixed at or above a ratio of 8:2 with factor VII-depleted plasma, 7:3 with factor IX- or factor X-depleted plasmas, or 2:8 with factor II-, V- or VIII-depleted plasmas. (
  • The model is responsive to alterations in the concentrations of factor VIII, factor V, and their respective activated species, factor VIIIa and factor Va, and overall provides a reasonable approximation of empirical data. (
  • The present Pharmacopoeia Monograph applies to methods used to determine activity of human blood coagulation factors I, II, VII, VIII, IX, X, XI, von Willebrand factor, and antithrombin III in plasma and blood preparations. (
  • Aims: Factor VIII (FVIII) replacement therapy remains a primary treatment for hemophilia A, however, the development of FVIII antibodies (inhibitors) and short half-life of the FVIII products are the major complications. (
  • Young, G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. (
  • A deficiency in blood coagulation factor VIII (fVIII) is responsible for the inherited bleeding disorder hemophilia A, which affects approximately 1 in 5000 males. (
  • Wuerth, Michelle E., "Structural Studies of Blood Coagulation Factor VIII in Protein Complexes" (2015). (
  • Blood coagulation factor VIII: An overview. (
  • Factor VIII (FVIII) functions as a co-factor in the blood coagulation cascade for the proteolytic activation of factor X by factor IXa . (
  • Dependent variables were categorized into three groups including 1.Coagulation: fibrinogen (FIB), factor VIII (FVIII), prothrombin time (PT), prothrombin time activity (PTA), international normalized ratio (INR), activated partial thromboplastin time(aPTT), platelet (PLT), mean platelet volume (MPV) 2. (
  • Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). (
  • In humans, factor VIII is encoded by the F8 gene. (
  • Factor VIII is produced in liver sinusoidal cells and endothelial cells outside the liver throughout the body. (
  • In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. (
  • The factor VIII gene produces two alternatively spliced transcripts. (
  • People with high levels of factor VIII are at increased risk for deep vein thrombosis and pulmonary embolism. (
  • Copper is a required cofactor for factor VIII and copper deficiency is known to decrease levels of factor VIII. (
  • Factor VIII was first characterized in 1984 by scientists at Genentech. (
  • The gene for factor VIII is located on the X chromosome (Xq28). (
  • The gene for factor VIII presents an interesting primary structure, as another gene is embedded in one of its introns. (
  • Factor VIII protein consists of six domains: A1-A2-B-A3-C1-C2, and is homologous to factor V. The A domains are homologous to the A domains of the copper-binding protein ceruloplasmin. (
  • Activation of factor VIII to factor VIIIa is done by cleavage and release of the B domain. (
  • Factor VIII is not affected by liver disease. (
  • the incidence of these inhibitors is dependent of various factors, including the factor VIII product itself. (
  • In the 1980s, some pharmaceutical companies such as Baxter International and Bayer sparked controversy by continuing to sell contaminated factor VIII after new heat-treated versions were available. (
  • Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? (
  • These approaches include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab. (
  • Hemophilia A is an X-linked bleeding disorder caused by defects in the gene encoding factor (F)VIII affecting 1 or 2 per 10 000 male births. (
  • The genetic disorders responsible for hemophilia A result in low levels or abnormal production of the clotting protein factor VIII (FVIII). (
  • levels of blood clotting factors VIII or IX. (
  • A method of preparing high purity procoagulant protein comprising the steps of (a) adsorbing a VIII:C/VIII:RP complex from a plasma or commercial concentrate source of factor VIII onto agarose beads bound to a monoclonal antibody specific to VIII:RP, (b) eluting VIII:C with a salt solution, (c) adsorbing. (
  • 15. In a method for purifying Factor VIII procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate through a chromatographic type column having adsorbent to which is bound monoclonal antibodies which is specific to VIII:RP and eluting the VIII-C therefrom. (
  • This invention relates generally to a method of separating and purifying factor VIII procoagulant activity protein. (
  • More specifically, high purity factor VIII procoagulant activity protein is separated from von Willebrand Factor by a two step chromatographic adsorption and concentration technique from plasma or concentrate. (
  • The precise structure of the antihemophilic factor, also referred to as factor VIII procoagulant activity protein (factor VIII), has not yet been identified, due in part to the unavailability of sufficient quantities of pure material with which to conduct further studies. (
  • ADYNOVATE belongs to the group of medicines called blood coagulation factor VIII. (
  • It is used for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). (
  • ADYNOVATE contains the active substance rurioctocog alfa pegol, pegylated human recombinant coagulation factor VIII. (
  • The human coagulation factor VIII is produced by recombinant DNA technology and has been modified chemically to prolong its duration of action. (
  • Under normal physiological condition, factor VIII is essential for blood clotting and maintenance of a bleeding episode. (
  • Individuals with haemophilia A disease, which is a hereditary disorder of blood coagulation have a low level of factor VIII in their blood circulation. (
  • As a result of factor VIII deficiency, the individual with this disease may have a heavy bleeding into joints, muscles or internal organs either spontaneously or as a result of accidental or surgical trauma. (
  • ADYNOVATE is similar to plasma-derived factor VIII. (
  • For each bleeding episode, administer the first dose of von Willebrand factor (recombinant) with an approved recombinant (non-von Willebrand factor containing) factor VIII [antihemophilic factor (recombinant)] if factor VIII baseline levels are below 40% or are unknown. (
  • a If recombinant factor VIII is administered, see recombinant factor VIII package insert for reconstitution and administration instructions. (
  • If recombinant factor VIII is required, give recombinant factor VIII within 10 minutes of completing von Willebrand factor (recombinant) infusion at a ratio of 1.3:1 (i.e., 30% more von Willebrand factor [recombinant] than recombinant factor VIII, based on the approximate mean recoveries of 1.5 and 2.0 IU/dL for von Willebrand factor [recombinant] and recombinant factor VIII, respectively). (
  • Consult the package insert for the specific factor VIII product for dosing recommendations. (
  • In patients requiring frequent doses of von Willebrand factor (recombinant) with recombinant factor VIII, monitor plasma levels for FVIII:C activity because an excessive rise in factor VIII levels can increase the risk of thromboembolic complications. (
  • Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. (
  • Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. (
  • Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII. (
  • Effective treatment of bleeding symptoms should be based upon the clinical situation and depends on the inhibitor characteristics against human and porcine factor VIII. (
  • Immunosuppression usually does not significantly affect the disappearance of the factor VIII inhibitor antibody. (
  • Bovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (like suture, ligature, or cautery) is ineffective or impractical [FDA Label]. (
  • To analyze the prothrombotic potential in a long-term follow-up on Fontan patients via plasma contribution to thrombin and factor (F)Xa generation profiles. (
  • Thrombin and FXa generation was simulated from plasma concentrations of FII, FV, FVII, FVIII, FIX, FX, antithrombin and tissue factor (TF) pathway inhibitor from Fontan patients (n = 48) and healthy controls (n = 34). (
  • Results and Conclusion: The average yield of the CO was 7-fold higher than WT, while both proteins were identical in the amino acid sequences (99% coverage) and very similar in patterns of the molecular fragments (before and after thrombin cleavage), glycosylation and tyrosine sulfation, secondary structures and binding to von Willebrand factor and to a fragment of the low-density lipoprotein receptor-related protein 1. (
  • Factor Xa is a serine protease which activates thrombin and plays a significant role in blood coagulation pathway. (
  • Factor X is the starting Factor of the final pathway or also known as thrombin pathway [ 1 ]. (
  • Previous studies suggested that FVIIa/TF activates FVIII rapidly in immediate coagulation reactions, and FVIIa/TF/FXa activates FVIII prior to thrombin-dependent feedback. (
  • Binding of FVIIIa to FIXa onto the platelet surface increases Factor Xa (FXa) and Thrombin generation more than 10^6 times. (
  • 1994 (PMID:8083241) This model is described in the article: A model for the tissue factor pathway to thrombin. (
  • The reaction sequence is initiated by the expression of tissue factor on the surface of activated cells and results in the generation of thrombin, the most important enzyme in blood clot formation. (
  • Thrombin converts soluble fibrinogen, via soluble fibrin monomers, into the insoluble fibrin that forms the matrix of a blood clot as well as exerting positive-feedback regulation that effectively promotes additional thrombin generation that facilitates the rapid development of a thrombus. (
  • Objective: To determine whether FXIa promotes thrombin generation and coagulation in plasma in the absence of FIX, and to determine whether FXI-deficiency produces an antithrombotic effect in mice independently of FIX. (
  • Methods: FXIa, FXIa variants and anti-FXIa antibodies were tested for their effects on plasma coagulation and thrombin generation in the absence of FIX, and for their effects on the activation of purified coagulation factors. (
  • Upon activation by thrombin (factor IIa), it dissociates from the complex to interact with factor IXa in the coagulation cascade. (
  • It is a cofactor to factor IXa in the activation of factor X, which, in turn, with its cofactor factor Va, activates more thrombin. (
  • Thrombin cleaves fibrinogen into fibrin which polymerizes and crosslinks (using factor XIII) into a blood clot. (
  • In our body, the blood protein Fibrinogen , a soluble plasma glycoprotein, synthesized by the liver, which gets as a protein precursor converted by thrombin into fibrin during blood coagulation. (
  • In our body's blood, fibrinogen is a plasma acute-phase protein clotted by thrombin , composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds, encoded by 3 separate genes on the long arm of chromosome 4.1. (
  • In our body, Fibrinopeptides A , as coagulation factors , are two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the coagulation process. (
  • Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. (
  • The 62 kDa proenzyme is activated by thrombin bound to an endothelial surface receptor and the active enzyme cleaves factor Va and VIIIa inhibiting blood coagulation. (
  • A fibrin-stabilizing plasma enzyme (TRANSGLUTAMINASES) that is activated by THROMBIN and CALCIUM to form FACTOR XIIIA. (
  • It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. (
  • For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency. (
  • Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency [FDA Label]. (
  • A highly sensitive label-free assay for the determination of blood coagulation Factor XIII activity is demonstrated through the controlled assembly of peptide-functionalized gold nanoparticles (AuNPs). (
  • Activated Factor XIII catalyzes the formation of covalent crosslinking between peptide chains through ε-(γ-glutamyl)-lysine bonds leading to the aggregation of the AuNPs and consequently a red-shift of the localized surface plasmon resonance. (
  • The colorimetric assay reported here provides direct qualitative and quantitative analysis of Factor XIII activity with a limit of detection of 0.01 U mL −1 . (
  • Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. (
  • Activate factor XIII to XIIIa. (
  • The blood coagulation factor XIII (FXIII) plays a critical role in supporting coagulation and fibrinolysis due to both the covalent crosslinking of fibrin polymers, rendering them resistant to plasmin lysis, and the crosslinking of fibrin to proteins of the fibrinolytic system. (
  • The hypochlorite-mediated oxidation of the blood coagulation factor XIII (FXIII) at the different stages of its enzymatic activation is studied for the first time in this paper. (
  • Plasma coagulation factor XIII (FXIII) catalyzes the formation of covalent bounds between fibrin monomers, thus stabilizing the fibrin clot and increasing its resistance to fibrinolysis . (
  • Coagulation factor XIII A chain is a protein that in humans is encoded by the F13A1 gene. (
  • This gene encodes the coagulation factor XIII A subunit. (
  • Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. (
  • Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. (
  • Platelet factor XIII is composed of just 2 A subunits, which are identical to those of plasma origin. (
  • Coagulation factor XIII, A1 polypeptide has been shown to interact with F13B. (
  • Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. (
  • This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. (
  • Factor XIII Concentrate (Human) is given to people whose blood is lacking Factor XIII. (
  • Factor XIII Concentrate (Human) works by assisting your blood in the usual clotting process, thereby preventing bleeding. (
  • Factor XIII of blood coagulation as a nuclear crosslinking enzyme. (
  • Platelet Vinculin - A Substrate of Activated Factor-XIII. (
  • Patients reporting a current systemic bleeding tendency at study entry had significantly reduced factor XIII. (
  • What are the signs and symptoms of factor XIII (FXIII) deficiency? (
  • Shanbhag S, Ghosh K, Shetty S. Genetic basis of severe factor XIII deficiency in a large cohort of Indian patients: Identification of fourteen novel mutations. (
  • Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences. (
  • Thakker S, McGehee W, Quismorio FP Jr. Arthropathy associated with factor XIII deficiency. (
  • Duckert F. Documentation of the plasma factor XIII deficiency in man. (
  • Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. (
  • Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. (
  • Severe gastrointestinal vasculitis in Henoch-Schoenlein purpura: pathophysiologic mechanisms, the diagnostic value of factor XIII, and therapeutic options. (
  • L1880] The von Willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von Willebrand factor (vWF). (
  • Due to this deficiency, the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding. (
  • Indicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, or for perioperative management of bleeding in patients with mild hereditary Factor X deficiency [FDA Label]. (
  • For use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin K antagonist therapy. (
  • It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy. (
  • Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. (
  • Mutations in Factor Xa gene result in deficiency known as congenital Factor Xa deficiency. (
  • Congenital deficiency of Factor V is called parahemophilia. (
  • Acquired deficiency of factor V is seen in the case of antibodies and also associated with liver disease, carcinoma, tuberculosis, and DIC. (
  • PT and APTT are prolonged in factor V deficiency. (
  • Coagulation Factor X (Human) helps stop or prevent bleeding in those with hereditary Factor X deficiency. (
  • Coagulation Factor X (Human) is a prescription medication used to help stop or prevent bleeding in those with hereditary Factor X deficiency, a rare, inherited bleeding disorder. (
  • It can also be used to manage bleeding after surgery in patients with mild hereditary Factor X deficiency. (
  • The primary objective is to collect additional surgical data on the clinical effectiveness of Coagadex, in a post-marketing environment, for peri-operative hemostatic cover during major surgery in patients with moderate or severe hereditary factor X (FX) deficiency. (
  • Idelvion is a prescription medication used to treat children and adults with Hemophilia B. This medication replaces the clotting factor ( factor IX ) that is missing in people with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. (
  • In connection with the model of deficiency of coagulation factor XI in a mammals (Bos Taurus L) with autosomal recessive type of inheritance is particularly promising. (
  • Deficiency of coagulation factor XI in cattle is inherited autosomal recessive defect. (
  • On the contrary it has been found that deficiency of coagulation factor XI cattle (FXID) is a consequence of the insertion of nucleotide sequences within exon 12 of the gene FXI length of 76 base pairs. (
  • Phenotypically deficiency of factor XI (FXID) in calves is resulted in disturbance of blood clotting and characterized by prolonged bleeding from the umbilical cord and anemia. (
  • Cows which are heterozygous in deficiency of coagulation factor XI have colostrum pink color. (
  • We monitored the breeding sires and Holstein cows on the carrier of the genetic disease: deficiency of coagulation factor XI. (
  • Factor V deficiency is a bleeding disorder that is passed down through families. (
  • Factor V deficiency is caused by a lack of factor V. When certain blood clotting factors are low or missing, your blood does not clot properly. (
  • In the inherited form of factor V deficiency, a family history of a bleeding disorder is a risk factor. (
  • An undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. (
  • Based on a 5-yr experience in POC-supported coagulation management in liver transplantation 19 - 20 we developed and implemented an algorithm including POC-supported coagulation management in cardiovascular surgery, based on first-line therapy with specific coagulation factor concentrates, such as fibrinogen concentrate and prothrombin complex concentrate (PCC), combined with point-of-care thromboelastometry and impedance aggregometry. (
  • Systemic sclerosis was associated with significantly raised levels of von Willebrand factor antigen and fibrinogen. (
  • Fibrinogen (factor I) converts to Fibrin. (
  • The effect of alfalfa on coagulation system was exerted via increasing the blood level of fibrinogen and it had no effect on other indices. (
  • Blood coagulation factors and other proteins, with modulatory effects or modulated by the coagulation cascade have been reported to affect the pathophysiology of the central nervous system (CNS). (
  • These proteins, in fact, showed peculiar properties, being able to interfere with synaptic homeostasis other than coagulation itself. (
  • Endogenous substances, usually proteins, that are involved in the blood coagulation process. (
  • The market size of recombinant and plasma-derived coagulation factor products exceeded US$ 7.5 bln in 2008, the majority (US$ 5.5 bln) generated by recombinant proteins. (
  • Clotting factors are proteins that help form blood clots at the site of blood vessel injury. (
  • The model system provides a realistic accounting of the fates of each of the proteins in the coagulation reaction through a range of initiator (factor VIIa-tissue factor) concentrations ranging from 5 pM to 5 nM. (
  • The goal was to compare targeted MRM proteomics with conventional assays to assess concentration levels of coagulation- and fibrinolysis-related proteins. (
  • The plasma levels of pro- and anticoagulant proteins are important markers for venous thrombosis (VT) risk and can be affected by both genetic and acquired factors, including cancer. (
  • We used liquid chromatography coupled to multiple reaction monitoring (MRM) mass spectrometry to evaluate the concentrations of 31 coagulation- and fibrinolysis-related proteins in plasma from 25 healthy controls, 25 patients with VT, and 25 patients with VT who were also diagnosed with cancer. (
  • The plasma levels of functional pro- and anticoagulant proteins, as well as of pro- and antifibrinolytic factors, are important markers for venous thrombosis (VT) 1,2 risk and can be affected by both genetic and acquired factors. (
  • Hemophilia B, the second most common form of hemophilia, affects factor IX proteins (FIX) and accounts for almost twenty percent of hemophilia cases. (
  • Hemophilia C affects factor XI proteins, and is unusual in that it affects both males and females. (
  • Do not use in patients who have had life-threatening hypersensitivity reactions to von Willebrand factor (recombinant) or its components (mannitol, trehalose, sodium chloride, histidine, Tris, calcium chloride, polysorbate 80, and hamster or mouse proteins). (
  • Von Willebrand factor (recombinant) contains trace amounts of mouse immunoglobulin G (MuIgG) and hamster proteins less than or equal to 2 ng/IU von Willebrand factor (recombinant). (
  • Coagulation factors are proteins found in plasma, which help blood clot. (
  • Blood clotting is a complex process involving as many as 20 different proteins in blood plasma. (
  • These proteins are called blood coagulation factors. (
  • Normal blood clotting involves blood components, called platelets, and as many as 20 different plasma proteins. (
  • The human antihemophilic factor is indicated for the cases of hemophilia A, also known as classical hemophilia for the prevention and control of hemorrhagic episodes. (
  • Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. (
  • Reasons that cause coagulation issues include liver disease, thrombophilia and hemophilia. (
  • The inability for vWF to bind fVIII is the basis for another blood coagulation disorder, von Willebrand's disease type 2N, which can lead to hemophilia-type levels of fVIII in the blood and subsequent bleeding episodes. (
  • Defects in this gene result in hemophilia A, a recessive X-linked coagulation disorder. (
  • Other heredity-based hemophilia disorders may affect other blood clotting factors, but they occur rarely. (
  • Mild hemophilia occurs when clotting factor levels fall between six to thirty percent of normal levels. (
  • People with moderate hemophilia have between one and five percent of normal clotting factor levels. (
  • Severe hemophilia cases have extremely low levels of clotting factors, amounting to less than one percent. (
  • Activated blood coagulation factor XI may refer to: Coagulation factor IXa, an enzyme Coagulation factor XIa, an enzyme This disambiguation page lists articles associated with the title Activated blood coagulation factor XI. (
  • Factor X is a serine endopeptidase enzyme, also known as prothrombinase, thrombokinase of the coagulation cascade. (
  • Blood coagulation factor XIIIa is a calcium-dependent enzyme that covalently ligates fibrin molecules during blood coagulation. (
  • Addition of coagulation factors VII, X, IX, V and II to depleted plasmas shortened clotting and enzyme initiation times, and increased enzyme generation rates in a concentration-dependent manner. (
  • Only additions of factors IX and X from low-normal to high-normal levels shortened clotting times and increased enzyme generation rates. (
  • In temperature studies, below 47 °C, the decrease in the activation rate was not related to the thermal denaturation of enzyme or substrate, nor to the choice of activator enzyme (factor XIIa or kallikrein), nor to the species of factor XII (human or bovine) but to a behavior, designated a thermal transition, associated with the surface or the protein-surface interaction. (
  • Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa and the substrate factor X. By simultaneously binding enzyme and substrate, emicizumab mimics some part of the function exerted by the original cofactor, FVIII, in that it promotes colocalization of the enzyme-substrate complex. (
  • Catalytic subunit of blood coagulation factor X-activating enzyme. (
  • result in low levels of fibrin, which impairs the body's ability to create strong blood clots. (
  • It is important for stabilizing the formation of the fibrin polymer (clot) which culminates the coagulation cascade. (
  • These factors interact with other chemicals to form a substance that stops bleeding called fibrin. (
  • For this purpose, the present study was conducted to evaluate the effect of eight weeks of aerobic exercise on lipoprotein a, blood coagulation and fibrinolysis factors in overweight women. (
  • Eight weeks of aerobic training had no effect on Lipoprotein a and blood coagulation and fibrinolysis factors, however, this training program can take effective steps in improving health promotion in overweight women. (
  • Mutations in Factor Xa could be interfaced with thrombosis. (
  • The mechanism behind thrombosis in cancer may be circulating tissue factor (TF), as levels of circulating TF are associated with thrombosis. (
  • We hypothesize that coagulation factor levels regulate the kinetics of circulating TF-induced thrombosis. (
  • We hypothesize that individual patient factor IX and X levels may be prognostic for susceptibility to circulating TF-induced thrombosis. (
  • Human blood coagulation, haemostasis and thrombosis / edited by Rosemary Biggs. (
  • 9 15-19 In most cases, thrombosis was spontaneous and there were no known risk factors, although some patients with thrombocytosis after splenectomy developed venous thrombosis. (
  • Blood Coagulation Testing is a method used for diagnostics of the hemostasis system. (
  • Our goal is to define the active conformation (structure) of the membrane-bound complex(es) of blood coagulation factors essential for the aniticoagulant pathways of blood hemostasis. (
  • FVIII concentrated from donated blood plasma, or alternatively recombinant FVIIa can be given to hemophiliacs to restore hemostasis. (
  • Hemostasis and blood coagulation. (
  • The 3D structure for Factor Xa with PDBID:2VH6 was obtained from Protein data bank [ 11 ]. (
  • In general, it is thought that the mechanism involves the formation of a complex between tissue factor, a specific glycoprotein found on many cell types, and factor VII, a protein that circulates in the blood. (
  • In project 6, the emphasis will be on producing mutations in the tissue factor protein that will be used for structure/function studies in the other projects. (
  • A new fluorogenic peptide substrate for vitamin K-dependent blood coagulation factor, bovine protein C. (
  • This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. (
  • The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. (
  • Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. (
  • No longer protected by vWF, activated FVIII is proteolytically inactivated in the process (most prominently by activated protein C and factor IXa) and quickly cleared from the blood stream. (
  • Pre- eclampsia is defined by high blood pressure (hypertension), the loss of protein into the urine (proteinuria), and disorders of many body systems, including the blood clotting (coagulation) and inflammation. (
  • We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre- eclampsia by reducing coagulation and inflammation disorders. (
  • Nephrotic syndrome is a group of symptoms that include protein in the urine, low blood protein levels, high cholesterol levels, high triglyceride levels, and swelling. (
  • Discover related pathways, diseases and genes to Coagulation Factor XIV/Protein C. Need help? (
  • Activates coagulation factor X (F10) by cleaving the Arg-Ile bond and is also able to activate coagulation factor IX (F9) and protein S (PROS1) by specific cleavage of Arg-Ile and Arg-Val bonds. (
  • FDA approved a new formulation of the genetically engineered version of Factor VIIa, a plasma protein essential for the clotting of blood. (
  • Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids. (
  • THPH3, or Protein C, inactivator of coagulation factors Va and VIIIa, is a human gene encoded by PROC. (
  • Journal of Biological ChemistryVolume 277, Issue 21, 24 May 2002, Pages 18322 -18333 11893748, Abstract: We have developed a model of the extrinsic blood coagulation system that includes the stoichiometric anticoagulants. (
  • abstract = "Summary: Background: Factor XIa is traditionally assigned a role in FIX activation during coagulation. (
  • abstract = "The activation of factor XII by the proteases factor XIIa and kallikrein is known to be greatly enhanced by certain negatively charged surfaces. (
  • We investigated FVIII/FVIIa/TF/FXa relationships in early coagulation mechanisms. (
  • Overall, these data suggest that FVIII-associated intrinsic-Xa, governed by both FVIIa/TF-induced and FXa-induced FVIII activation mediated by FVIII-TF interactions, together with FVIIa-dependent extrinsic-Xa mechanisms, may be central to the initiation phase of coagulation. (
  • Mutations in FVIII result in mild to severe Haemophilia type A, a life-threatening blood condition affecting one in 5000 of the male population (Wacey et al. (
  • The greatest activation of FVIII in both groups including lysate and non-lysate FVIII-loaded RBCs was observed on the first day, and the coagulant activity of this factor was gradually reduced on days 3 and 5. (
  • Studies of the fVIII C2 domain were then extended to attempts to understand the structural basis for the interactions between fVIII and its circulatory partner von Willebrand factor (vWF), which is crucial for maintaining fVIII levels in plasma. (
  • 6 , 7 Currently, bleeding in inhibitor patients is managed using bypassing agents that work independently of FVIII, like recombinant activated factor VII and activated prothrombin complex concentrates. (
  • In the recombinant factor VIIa pipeline, all projects except one are modified versions, either short-acting or longer acting with four projects in the clinic and two more shortly to follow. (
  • This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. (
  • The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as cardiopulmonary bypass and other shunt procedures. (
  • Factor VIIa/tissue factor (FVIIa/TF) initiates blood coagulation by promoting FXa generation (extrinsic-Xa). (
  • The division of the coagulation system into intrinsic and extrinsic pathways does not found in vivo because activated factor VIIa can activate factor IX and X. (
  • NovoSeven RT-the new formulation of NovoSeven Coagulation Factor VIIa (Recombinant)-contains sucrose and L-Methionine, which allow for storage at room temperature. (
  • There is a cascade of coagulation factors needed for the proper coagulation. (
  • The role of serine proteases in the blood coagulation cascade. (
  • Bleeding disorders are a group of disorders that result when the blood cannot clot properly. (
  • Various abnormalities of coagulation and fibrinolysis occur in patients with thyroid diseases, and may range from subclinical laboratory abnormalities to clinically significant disorders of coagulation and, rarely, major haemorrhage or thromboembolism. (
  • Ragni MV. Hemorrhagic disorders: coagulation factor deficiencies. (
  • Hereditary clotting factor deficiencies (bleeding disorders). (
  • Bleeding disorders are a group of conditions in which there is a problem with the body's blood clotting process. (
  • Bleeding disorders can also result from a problem with the number or function of the blood cells that promote blood clotting (platelets). (
  • The "Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis" report is the most complete and up-to-date evaluation and assessment of the recombinant and plasma-derived coagulation factor pipelines. (
  • A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis" provides a description, evaluation and assessment of the recombinant coagulation factor R&D pipelines as of October 2011. (
  • TRANFUSION of packed red blood cells (PRBC), fresh frozen plasma (FFP), cryoprecipitate, and platelet concentrates is strongly associated with increased morbidity and mortality in cardiovascular surgery, patients with myocardial infarction, and critically ill patients. (
  • Whole blood platelet aggregation and coagulation factors in pa. (
  • Whole blood platelet aggregation and coagulation factors in patients with systemic sclerosis. (
  • Whole blood platelet aggregation was studied in 26 patients with systemic sclerosis, normal subjects matched for age, sex and secondary characteristics, 19 patients with Raynaud's disease and 19 patients with systemic lupus erythematosus. (
  • On an individual patient basis, von Willebrand factor antigen was related to the severity of the disease whereas platelet sensitivity to collagen was not. (
  • Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TF9-6B4 may be used in the claimed methods. (
  • Your body can also make antibodies, called "inhibitors," against coagulation Factor X, which may stop this medication from working properly. (
  • 2002) of blood coagulation simulating the effects of coagulation factor inhibitors, fondaparinux (synthetic heparin) and Rivaroxaban. (
  • Common side effects of coagulation Factor X (human) include pain and redness at the injection site and fatigue. (
  • The coagulation phase then causes a blood clot to form. (
  • A counter pathway ensures that the size of the growing blood clot stays in check. (
  • There was a strong association between clot formation time after surgery and blood loss (R = 0.68, p=0.001). (
  • The increase in blood loss was 4.1 ml for every one-second increase in clot formation time (95% CI 1.9 - 6.4, p=0.001). (
  • Blood coagulation recovered in factor deficient plasma after addition of the respective factor (Clot-based method). (
  • This interaction sets off a chain of additional chemical reactions that form a blood clot. (
  • Instead, bleeding lasts for longer than ordinary, due to the body's inability to form a blood clot. (
  • It affects the ability of the blood to clot. (
  • Taken together, our results showed that these factors were important features for fungal virulence in humans and suggested that thermolabile components in the blood serum may induce M. circinelloides virulence. (
  • 2016 -06-09 Hysteresis-like binding of coagulation factors x/xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization (Podoplelova et al. (
  • Next, circulating platelets clump along the site of blood vessel injury. (
  • Intraoperative cell salvage of the cardiopulmonary bypass residual volume can dilute platelets and coagulation factors. (
  • These work to activate substances in your blood to form clots and decrease bleeding episodes. (
  • Von Willebrand factor (recombinant) is a hemostatic. (
  • Coagulation factors are central to the action of these pathways. (
  • Blood coagulation model investigating effects of Xa-inhibitors (Rivaroxaban and Apixaban). (
  • Factor Xa (FXa) emerged as a promising target for effective anticoagulation and several FXa inhibitors are now available for the prevention of venous thromboembolism. (
  • Your healthcare provider may give you blood tests to check for inhibitors. (
  • Factor X is activated into Xa by Factor IX and Factor VII with its cofactor and tissue Factors. (
  • In project 3, we will be studying the regulation of the tissue factor gene in vascular tissue. (
  • In project 4, the kinetics of feed-back regulation on the tissue factor pathway of coagulation will be studied. (
  • This is a tissue factor and it will activate VII when blood is exposed to tissue fluid. (
  • In addition to the theoretical considerations involving the reactions of the tissue factor pathway, a physical constraint associated with the stability of the factor VIIIa-factor IXa complex has been incorporated into the model based upon the empirical observations associated with the stability of this complex. (
  • We report here a detailed study of the effect of O-fucosylation at Ser-60 on the structure of FVII EGF-1, its Ca2+-binding affinity, and its interaction with tissue factor (TF). (
  • Examples hereof are concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor, and fitusiran, an small interfering RNA approach to reduce expression of antithrombin. (
  • The pathophysiology of massive blood loss is complex, comprising a wide range of physiologic derangements arising from tissue injury, bleeding, and transfusion of blood or blood products. (
  • We report on two patients who underwent successful transplantation for posthepatitis viral cirrhosis, which developed following blood factor replacement for haemophilia A. The second patient was transplanted before the occurrence of major complications of either his liver or haemophilic disease. (
  • The effect of hydroalcoholic extract of Medicago sativa on liver function tests blood biochemical factors and coagulation system in male rats. (
  • The aim of this study was to evaluate the effect of hydroalcholic extract of Medicago sativa on liver function tests, blood biochemical factors and coagulation system parameters in male rats. (
  • Servatyari K, Ahmadi A, Kashefi H, Manbari M N, Rostami A, Moulodi M R. The effect of hydroalcoholic extract of Medicago sativa on liver function tests, blood biochemical factors and coagulation system in male rats. (
  • tumour necrosis factor α mRNA levels in liver and lung tissues from infected diabetic mice compared with those in tissues from animals infected with spores produced in the presence of YPG supplemented with denatured blood serum or of YPG alone. (
  • This complex is the pro-coagulant factor VIIIa. (
  • Degradation of blood coagulation factors Va and VIIIa. (
  • 3 - 13 Furthermore, blood transfusion is associated with prolonged hospital stay as well as increased hospital costs. (
  • Smaller studies suggest that implementation of point-of-care (POC) coagulation tests coupled to algorithm-based management decreases transfusion requirements in cardiac surgery. (
  • Blood transfusion in the last month will affect the result. (
  • II-20 Haemonetics Eyes the Whole Blood Market II-20 Fresenius Bolsters Transfusion Business with Inorganic Growth II-21 Distribution Channels. (
  • Transfusion of blood and blood products is usually necessary during a bleeding catastrophe. (
  • The process of ordering and checking blood may be cumbersome during massive blood transfusion. (
  • Transfusion of blood and blood products is not without negative consequences. (
  • Understanding the physiology of massive hemorrhage, initiating massive transfusion, and preparing adequate blood inventories are fundamental components of management. (
  • b A bleed could be considered major if red blood cell transfusion is either required or potentially indicated or if bleeding occurs in a critical anatomical site (e.g., intracranial or gastrointestinal hemorrhage). (
  • The disease is treated by chronic blood transfusion. (
  • 8 9 All these reports were from patients who were not given regular transfusions and were not associated with an individual blood transfusion. (
  • Other reports have described cases of hypertension, convulsion, and cerebral hemorrhage in thalassemic patients following blood transfusion. (
  • Thromboplastin activates factor X. (
  • Injury to body parts activates several systems, including the autonomic nervous system, the coagulation system, the fibrinolytic system, the complement system, and the systemic inflammatory response. (
  • 1 2 In this study, the prevalence of thromboembolic events was 3.3% among 421 patients with β-TM and 16.2% among 74 patients with β-TI, although 15.3% of these patients had predisposing congenital or acquired factors contributing to the hypercoagulability. (
  • DUBLIN, June 7, 2021 /PRNewswire/ -- The "Blood Plasma Products Market in India 2021" report has been added to's offering. (
  • Replacement of plasma-derived coagulation factors by marketed recombinant molecules is ongoing and will further increase by new recombinant coagulation factors in development. (
  • Prothrombin is a glycoprotein with a molecular weight of 71,600 daltons, present in the blood and plasma. (
  • This factor is not destroyed or consumed during the clotting process, so it is found in the serum and in the plasma. (
  • One IU (100 %) is the activity of a coagulation factor in 1.0 mL of fresh normal pooled plasma obtained from 300 donors. (
  • Factor II is determined using human factor II-deficient plasma as the substrate. (
  • Transfer 50 µL of the factor II-deficient plasma and 50 µL of the standard or tested sample dilution into a plastic test tube. (
  • Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. (
  • Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. (
  • The isolation of the antihemophilic factor from blood plasma has been described in the literature. (
  • You will be given fresh blood plasma or fresh frozen plasma infusions during a bleeding episode or after surgery. (
  • Site-directed mutagenesis of the calcium-binding site of blood coagulation factor XIIIa. (
  • Calcium in the blood, 50% is ionized and a very small amount is needed in the clotting mechanism. (
  • The coagulation process is activated by addition of a calcium thromboplastin mixture. (
  • Coagulation time starts from the moment 200 µL of calcium thromboplastin pre-heated to 37 ± 0.5 °С is added to the mixture. (
  • The aim of this study was to investigate the effect of one bout submaximal endurance exercise on blood coagulation and fibrinolytic factors in patients with hypertension. (
  • Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates. (
  • The major factors contributing to the market growth is essentially determined by the expanding increase in population of cardiovascular diseases, increase in prevalence of death due to diabetic population, rise in geriatric population and rising awareness of diabetes. (
  • Prevalence of hypertension and associated cardiovascular risk factors in an urban slum in Nairobi, Kenya: a population-based survey. (
  • In this cases, the human antihemophilic factor may be administered followed by intermittent maintenance doses. (
  • In the blood, it mainly circulates in a stable noncovalent complex with von Willebrand factor. (
  • This preparation does not contain von Willebrand factor and is therefore not suitable for use in von Willebrand's disease. (
  • Von Willebrand factor (recombinant) is a recombinant von Willebrand factor (VWF) indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD). (
  • Von Willebrand factor (recombinant) is available as a lyophilized powder in single-use vials containing nominally 650 or 1300 international units von Willebrand factor activity (VWF:RCo). (
  • Administer von Willebrand factor (recombinant) within 3 hours after reconstitution. (
  • If signs and symptoms of severe allergic reactions occur, immediately discontinue administration of von Willebrand factor (recombinant) and provide appropriate supportive care. (
  • Thus, with each step in the pathway, more and more factors are activated. (
  • Frequently the etiologic factor of most hidden genetic defects in animals are point mutations in the coding region of the respective genes. (
  • 14 - 18 However, these studies vary widely with respect to the scope of POC measurements performed, availability and use of coagulation factor concentrates, and by consideration of either the intraoperative or postoperative period. (
  • McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. (
  • Prothrombin is a vitamin K dependent clotting factors. (
  • It is most abundant and has the longest half-life of the vitamin K dependent clotting factors. (
  • This is a vitamin K- dependent factor. (
  • Rather, changes in B-factor ratios between the C2 complexes and the isolated C2 domain suggest that dynamic changes upon 3E6 binding may lead to more favorable binding of a second antibody on the protein's opposite face. (
  • Therefore, the aim of the present study was to investigate the markers of endogenous coagulation and fibrinolysis, and to evaluate the relationships between serum lipid profile and thyroid hormones and these haemostatic parameters in subclinical thyroid patients. (
  • Blood clots. (
  • Hyperfibrinolysis destroys stable blood clots, and antifibrinolytic agents may be required. (
  • it is a cofactor for factor IXa which, in the presence of Ca2+ and phospholipids, forms a complex that converts factor X to the activated form Xa. (
  • Subject matter wherein the peptide composition is related to fibrinopeptides, blood-coagulation factors or derivative. (
  • At the second stage, the amount of the produced activated factor is determined by the reaction in which it breaks down a specific chromogenic peptide (Chromogenic method). (